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EXPRESSION OF GENES FOR PEPTIDE/PROTEIN HORMONES AND THEIR 
COGNATE RECEPTORS IN BREAST CARCINOMAS AS BIOMARKERS 
PREDICTING RISK OF RECURRENCE 
Michael W. Daniels 
May 14, 2016 
Certain hormones and/or receptors influencing normal cellular pathways 
were detected in breast cancers.  The hypothesis is that gene subsets predict risk 
of breast carcinoma recurrence in patients with primary disease. Gene expression 
of 55 hormones and 73 receptors were determined by microarray with LCM-
procured carcinoma cells of 247 de-identified biopsies. Univariate and multivariate 
Cox regressions were determined using expression levels of each 
hormone/receptor gene, individually or as a pair. Significant genes derived for each 
subset were analyzed to predict risk of cancer recurrence with 1000 LASSO 
training/test sets. A 14-gene molecular signature was identified for predicting 
clinical outcome without regard to estrogen or progestin receptor status of 
biopsies. A three-gene signature was derived for ER+ cancers while a 9-gene 
signature was deciphered for ER- cancers. Molecular signatures derived were 
compared with results in public databases. Collectively, results suggest gene 









LIST OF TABLES……………………………………………………………………… vi 
LIST OF FIGURES…….……………………………………………………………… vii 
CHAPTER I……………..………………………………………………………………. 1 
CHAPTER II UNIVARIATE ANALYSES……………………………………………... 8 
Method and Materials…………………….……………………………………. 9 
Microarray Database……………..……………………………………. 9 
Gene Expression Analyses…………………………………….……. 11 
Preliminary Gene Selection………………………………………….. 11 
Univariate Cox Regression….……………………………………….. 12 
Influence of Estrogen Receptor and Progestin Receptor 
 Status on Gene Expression Levels……...…………………………. 14 
 Results…………………………………………………………………………. 15 
Univariate Cox Regression of PFS and OS without 
 Regard to ER and PR Status…………………………………...….... 15 
  Univariate Cox Regression of PFS and OS According 
    to ER Status…………………………………………………………... 16
vii 
 
Univariate Cox Regression of PFS and OS According 
 to PR Status…………………………………………………………... 20 
Univariate Cox Regression of PFS and OS  
 According to ER/PR Status…...…………………………...………... 23 
  Analyses of Clinical Relevance using Kaplan-Meier Plots…......… 25 
Evaluation of Influence of Steroid Hormone Receptor 
 Status using Boxplots…………………………………...…………… 27 
 Discussion……………………………………………………………………... 32 
CHAPTER III MULTIVARIATE ANALYSES……………………………………….. 36 
Method and Materials…………………….…………………….…………….. 37 
Multivariate Cox Regression……..……………….…………………. 37 
Least Absolute Shrinkage and Selection Operator……………….. 38 
 Results…………………………………………………………………………. 39 
Multivariate Cox Regression with Interaction of PFS 
 and OS without Regard to ER and PR Status 
 of the Cancer Biopsy.………………………………………………… 39 
Multivariate Cox Regression with Interaction of PFS 
 and OS with Regard to ER and PR Status 
 of the Cancer Biopsy……………………………………….………… 40 
Multivariate Cox Regression for the Genes of 
 Hormones of PFS and OS without Regard to  
ER and PR Status of the Cancer Biopsy…………………………… 47 
Multivariate Cox Regression for the Genes of 
viii 
 
 Receptors of PFS and OS without Regard to 
 ER and PR Status of the Cancer Biopsy………………….…...….. 49 
Kaplan-Meier Plots Discriminating Hormone-Receptor 
 Pairs Whose Expression Levels Predict Clinical Outcomes.......... 53 
Multivariable Gene Expression Model Fitted using LASSO……… 54 
 Discussion……………………………………………………………………... 57 
 
CHAPTER IV META-ANALYSIS AND MOLECULAR SIGNATURES…….……. 60 
Method and Materials…………………….…………………………………... 60 
Public Databases…………..……..…………………………………... 60 
Molecular Signatures and Multivariable Cox Model………………. 62 
Results…………………………………………………………………………. 64 
Meta-analysis of HRL and Four Public Databases.……..…………. 65 
Kaplan-Meier Plots Demonstrating Results from Meta-Analysis… 67 
Gene Signatures Predicting Clinical Behavior of Breast 
Carcinomas.…………………………………………………………… 67 
 Discussion……………………………………………………………………... 73 
References…………………………………………………………………………….. 76 
Curriculum vitae…………………………………………………………….………… 81 
ix 
 
LIST OF TABLES 
TABLE                                                                                                            PAGE 
1.   Summary of Patient Characteristics in Microarray Database..............…….... 10 
2.   Summary of Genes with Expression Levels Associated with PFS............…. 18 
3.   Summary of Genes with Expression Levels Associated with OS…............... 19 
4.   Summary of Genes with Expression Levels Correlating Either with 
 PFS (A) or OS (B) for 146 ER+ Breast Carcinomas……......…………….. 21 
5.   Summary of Genes with Expression Levels Correlating either with 
  PFS (A) or OS (B) for 101 ER- Breast Carcinomas..……...................….. 21 
6.   Summary of Genes with Expression Levels Associated either with 
 PFS (A) or OS (B) for 151 PR+ Breast Carcinomas………………………. 22 
7.   Summary of Genes with Expression Levels Associated with PFS 
  for 96 PR- Breast Carcinomas………...………………………….………..... 23 
8.   Summary of Genes with Expression Levels Associated with 
  OS for 118 ER+/PR+ Breast Carcinomas…………...……….………......... 28 
9.   Summary of Genes with Expression Levels Associated with 
  PFS for 28 ER+/PR- Breast Carcinomas……....………………………....... 28 
10.  Summary of Genes with Expression Levels Associated with 
  PFS for 68 ER-/PR- Breast Carcinomas………………………….………… 28 
x 
 
11.  Summary of the Interaction Term for Hormone and Receptor 
 Gene Pairs with Expression Levels Associated with OS 
 without Regard to Receptor Status…………………….....………………… 40 
12.  Summary of the Interaction Term for Hormone and Receptor 
 Gene Pairs with Expression Levels Associated with OS 
 for 146 ER+ Breast Carcinomas……………………………………….....…. 41 
13.  Summary of the Interaction Term for Hormone and Receptor 
 Gene Pairs with Expression Levels Associated with OS 
 for 101 ER- Breast Carcinomas………………......…………………………. 42 
14.  Summary of the Interaction Term for Hormone and Receptor 
 Gene Pairs with Expression Levels Associated with OS 
 for 151 PR+ Breast Carcinomas…….………………………………………. 43 
15.  Summary of the Interaction Term for Hormone and Receptor 
 Gene Pairs with Expression Levels Associated with OS 
 for 96 PR- Breast Carcinomas………………………………………………. 44 
16.  Summary of the Interaction Term for Hormone and Receptor 
 Gene Pairs with Expression Levels Associated with PFS  
 for 118 ER+/PR+ Breast Carcinomas………………………………………. 44 
17.  Summary of the Interaction Term for Hormone and Receptor 
 Gene Pairs with Expression Levels Associated with OS 
 for 28 ER+/PR- Breast Carcinomas…………………………………………. 45 
18.  Summary of the Interaction Term for Hormone and Receptor 
 Gene Pairs with Expression Levels Associated with either 
xi 
 
 PFS (A) or OS (B) for 33 ER-/PR+ Breast Carcinomas……………….….. 46 
19.  Summary of the Interaction Term for Hormone and Receptor  
 Gene Pairs with Expression Levels Associated with OS 
 for 68 ER-/PR- Breast Carcinomas…………………………………………. 47 
20.  Summary of the Hormone Term from Two Variable Cox 
 Models of Hormone and Receptor Gene Pairs with  
 Expression Levels Associated with PFS…………..……………………….. 48 
21.  Summary of the Hormone Term from Two Variable Cox  
 Models of Hormone and Receptor Gene Pairs with  
 Expression Levels Associated with OS……………………………..……… 49 
22.  Representative Summary of the Receptor Term from  
 Two Variable Cox Models of Hormone and Receptor  
 Gene Pairs with Expression Levels Associated with PFS…………….….. 51 
23.  Representative Summary of the Receptor Term from  
 Two Variable Cox Models of Hormone and Receptor  
 Gene Pairs with Expression Levels Associated with OS…………….....… 52 
24.  Significant Genes and Corresponding Beta Coefficients  
 for LASSO Performed on 142 Peptide/Protein Hormones  
 and Their Cognate Receptors with and without Receptor  
 Status of Breast Carcinomas……………………........................…………. 57 
25.  Summary of the Genes from Meta-analysis without Regard 
 to Receptor Status (n=1126) with Expression Levels  
 Associated with PFS/DMFS………………………..........………………….. 65 
xii 
 
26.  Summary of the Meta-analysis for (A) ER+ (n=737) and  
 (B) ER- (n=378) Breast Cancers with Expression Levels  






LIST OF FIGURES 
FIGURE                                                                                                         PAGE 
1.  Flow Diagram of Approaches and Analyses used to Decipher 
 Clinically Relevant Molecular Signatures………..………………….....…….. 7 
2.  Representative Kaplan-Meier Plots Comparing Above and Below  
 the Median Relative Gene Expression (1)……………..………….….....…. 29 
3.  Representative Kaplan-Meier Plots Comparing Above and Below 
  the Median Relative Gene Expression (2)……………….…………………. 30 
4.  Representative Boxplots Comparing Distributions of Relative  
 Gene Expressions by Receptor Status……………………………...……... 31 
5.  Representative Kaplan-Meier Plots Comparing Above and Below  
 the Median Relative Gene Expression for Peptide/Protein  
 Hormones and Their Cognate Receptors……………………….……....…. 56 
6.  Representative Kaplan-Meier Plots Comparing Above and Below  
 the Median Relative Gene Expression of 142 Peptide/Protein  
 Hormones or Their Cognate Receptors with and without Regard 
 to ER Status for PFS from the Meta-analysis…………...…………………. 70 
7.  Composition of Molecular Signatures Derived Showing Genes  
 Common to Each………………………………………….………………….. 71 
8.  Summary of 1000 C-indices of Each of the Three Molecular  
 Signatures on Each of the Four Public Databases, (A) VDX,  
xiv 
 





 The Surveillance, Epidemiology, and End Results (SEER) program 
estimated 231,840 new breast cancer cases and 40,290 deaths in the United 
States in 2015 ("Surveilance, Epidemiology, and End Results Program,"). Self-
examination to clinical examination to mammogram is a typical route to detect 
breast cancer. When an area of the breast is identified as suspicious, a biopsy may 
be taken to help classify a tumor as malignant. If the tumor is diagnosed as 
carcinoma, then the pathologist will evaluate the lesion by stage and type. Stage 
is based on several factors such as size of the cancer, number of lymph nodes 
involved and signs of local invasion of the breast and metastasis to other organs 
(Greenspan, Gardner, & Shoback, 1997). Some types of breast cancer may be 
characterized as in situ versus invasive, ductal versus lobular and sex-hormone 
receptor status (Fleisher, Dnistrian, Sturgeon, Lamerz, & Wittliff, 2002; J. Wittliff, 
Pasic, & Bland, 1998). Classification of stage and grade as well as nodal status 
contributes significantly to determining the prognosis and treatment of the disease.   
An important consideration for assessing breast cancer prognosis and 
treatment was provided by the discovery that estrogen (ER) and progestin
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receptor (PR) proteins were clinically useful biomarkers (Fisher et al., 1983; Fisher 
et al., 1981; Fleisher et al., 2002; Hammond et al., 2010; James, 1984; J. Wittliff 
et al., 1998). Briefly, the presence of significant levels of ER and PR in a breast 
cancer biopsy was correlated with better prognosis than patients with lesion 
lacking ER and PR proteins. In addition, the presence of ER and PR in a breast 
cancer tissue biopsy was strongly associated with the patient’s response to 
Tamoxifen, an antiestrogen-like drug that binds to ER (Fisher et al., 1983; Fisher 
et al., 1981). Receptor status is now used as a combination of ER and PR with the 
addition of epidermal growth factor receptor-2 (HER-2/neu) protein, which is 
involved in growth regulation of cancer cells given their presence in the cell 
(Fleisher et al., 2002; Hammond et al., 2010).  
Common treatments for breast cancers with elevated levels of ER and PR 
are the antiestrogen-like drugs (e.g., Tamoxifen, Evista/Raloxifene and 
Fareston/Toremifene), which are termed SERMs (Selective Estrogen Receptor 
Modulators) ("Raloxifene Hydrochloride," ; "Tamoxifen Citrate," ; "Toremifene,"). 
Aromatase Inhibitors such as Arimidex (Anastrozole) and Femara (Letrozole), 
which block the production of estrogens from androgenic precursors produced by 
the adrenal glands, are used as hormone therapies for post-menopausal patients 
(Hong & Chen, 2011). HER/2 oncoprotein serves as a biomarker for treating a 
patient with the drug Trastuzumab (Herceptin) which attaches itself to the HER-
2/neu protein that is present in the surface membranes of certain breast carcinoma 
cells. For decades the Hormone Receptor Laboratory, which holds both CLIA and 
Commonwealth of Kentucky licenses as a Clinical Laboratory, has determined the 
3 
 
levels of these biomarkers in thousands of breast cancer tissue biopsies for 
management of patients.   
One area of research that is likely to improve the survival rates of women 
diagnosed with breast cancer is personalized or precision medicine. Due to the 
clinical and molecular heterogeneity of breast cancer, identifying genes and gene 
products involved in driving the progression of the disease may provide 
opportunities to design and synthesize new drugs for these new molecular targets. 
In addition, knowledge of their expression in relationship to risk of breast cancer 
recurrence provides additional information regarding a patient’s prognosis. Thus 
research in these areas of genomics and proteomics hold promise for developing 
a larger arsenal of personalized treatment options for breast cancer patients. 
Expression patterns of sets of genes that accurately predict the clinical behavior 
of cancers are called molecular signatures. Many genomics based signatures have 
been shown effective in predicting clinical outcomes such as progression free 
survival, which measures the length of time a patient lives without the appearance 
of a metastasis of the disease. (Gingras, Desmedt, Ignatiadis, & Sotiriou, 2015; J. 
Wittliff et al., 2002). A number of gene expression profiles (i.e., molecular 
signatures) have been developed and commercialized.  
It is widely documented that numerous peptide/protein hormones such as 
insulin act as growth factors impacting carcinoma cell growth and may play a role 
in carbohydrate metabolism during differentiation and growth of the lesion (Chen 
et al., 2002; Falzon & Du, 2000). Each of the hydrophilic peptide/protein hormones 
circulate freely in the blood and bring about their particular physiological actions in 
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normal target cells by associating with high affinity with their cognate receptor 
proteins which are located on cell surfaces (Norman & Litwack, 1997; Pierce, 
1982). Thus this diverse family of hormones which influences a wide variety of 
normal cellular pathways in the many organs composing the endocrine system 
when bound to their cognate receptor proteins provides a fertile and unchartered 
area to explore in breast cancer. The overarching goal of this study is to determine 
the relationships of the expression of the genes for each of the peptide/protein 
hormones and that of their cognate receptors with clinical outcomes of breast 
cancer patients. Our hypothesis is that expression profiles of subsets of these 
genes may be used to predict risk of breast carcinoma recurrence in patients with 
primary disease.   
To the best of our knowledge, no study has analyzed collectively the gene 
expression patterns of all of the peptide/protein hormones and their cognate 
receptors in relationship to their association with breast cancer behavior. The 
association of a peptide/protein hormone with its cognate receptor results in the 
release of signaling molecules (second messengers) inside the cell to trigger a 
variety of physiological changes ("Journal of receptor and signal transduction 
research," 1995).  
Peptide/protein hormones are produced and secreted by organs of the 
endocrine system throughout our bodies affecting adjacent cells (paracrine action) 
and cells located in distant organs (endocrine action).  For example, insulin and 
glucagon are produced by the pancreas and secreted into the bloodstream where 
they influence a variety of other organs to control blood sugar levels. Surprisingly, 
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breast carcinoma cells have been found to overexpress some of these hormone 
and receptor genes (Chen et al., 2002; Falzon & Du, 2000). From a variety of 
previous reports addressing relationships of hormones and cancer, and my co-
mentor’s years of experience investigating endocrine mechanisms of breast 
cancer, the following questions were developed. Do certain breast carcinomas 
express elevated levels of mRNA for genes of peptide/protein hormones and their 
cognate receptors? Are the gene expression levels related to clinical outcomes of 
the patients? Can one discern gene expression profiles (i.e., molecular signatures) 
that may be useful clinically in predicting risk of breast cancer recurrence?  
To begin to answer these questions we took a step-wise global approach 
using the gene expression levels of 22,000 genes that had been determined by 
microarray of RNA isolated from LCM-procured breast carcinoma cells (Figure 1 
Flow Diagram). Determination of which peptide/protein hormones and their 
cognate receptors may be playing a role in the clinical behavior of breast cancers 
required surveying research literature describing the diverse family of endocrine 
regulators as will be described in Chapter II. Due to the complicated nature of 
analyzing multiple genes and various breast cancer subtypes, the statistical 
analyses were performed in a stepwise manner as outlined in the flow diagram in 
Figure 1. Each of the following Chapters (II, III and IV) describes the manner in 
which the investigations were conducted, the results in the comprehensive 
databases that were employed and the statistical methods used for the analyses 
to identify interrelationships. These relationships are the essence of our hypothesis 
that expression profiles of subsets of genes for peptide/protein hormones and their 
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cognate receptors may be used to predict risk of breast carcinoma recurrence in 
patients with primary disease.  
In Chapter II, we evaluate univariate association of each of the identified 
hormone and receptors with breast cancer progression and overall survival. The 
univariate analyses in Chapter II will be extended to associations by ER/PR status. 
In a similar fashion ER/PR will be evaluated in Chapters III and IV. Multivariate 
analyses performed on hormone and receptor gene pairs in Chapter III explore an 
exhaustive evaluation of the relationships between hormones and their cognate 
receptors. Also in Chapter III, regularization techniques are employed to analyses 
all 142 genes at one time. In Chapter IV, a meta-analysis was performed with 
public databases to compare our results with a few highly referenced databases. 
Molecular signatures close out our analyses in Chapter IV as described in the Flow 
Diagram (Figure 1). The Flow Diagram is a recipe of approaches to develop 
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The microarray, protein biomarker and clinical follow-up databases used for 
analyses described in these investigations were established by my Co-mentor, Dr. 
Wittliff and collaborators almost two decades ago. (Sarah A Andres et al., 2015; 
Andres, Brock, & Wittliff, 2013; Andres, Edwards, & Wittliff, 2012; Andres & Wittliff, 
2011, 2012; Kerr II & Wittliff, 2011; Kidd et al., 2010; Kruer, Cummins, Powell, & 
Wittliff, 2013; Ma et al., 2003; Tecimer et al., 2000; J. Wittliff et al., 1998; J. L. 
Wittliff, 2010) Briefly, intact frozen tissue sections of de-identified human breast 
carcinoma tissue biopsies as well as those that were processed for a sophisticated 
technique called Laser Capture Microdissection (LCM) for the microarray analyses 
allowed collection of specific cell types in a non-destructive manner. (Andres & 
Wittliff, 2011, 2012) The results collected from microarray of LCM-procured cells 
are truly unique in that only the expressions of carcinoma cell genes were 
determined. This database was complemented by results in other comprehensive 
databases that contained quantitative results of protein biomarker levels (ER, PR 
and HER-2) that are used routinely in clinical management of breast cancer, qPCR 
validated expression levels of almost 100 genes as well as extensive results on 




Methods and Materials 
Microarray Database  
Using an IRB-approved biorepository and associated databases composed 
of tissue specimens previously collected by Dr. Wittliff’s laboratory (CLIA and 
Commonwealth of Kentucky licensed) at the University of Louisville for clinical 
assays of estrogen (ER) and progestin receptors (PR), de-identified tissue 
specimens of primary breast cancers obtained from 1988 - 1996 were examined 
using REMARK criteria (McShane et al., 2006) as described in previous studies. 
(Sarah A Andres et al., 2015; Andres et al., 2013; Andres & Wittliff, 2011; Kerr II & 
Wittliff, 2011; Kruer et al., 2013) Patients were treated with the standard of care at 
the time of diagnosis. Tissue-based properties (e.g., pathology, grade, size, and 
tumor marker expression) and patient-related characteristics (e.g., age, race, 
smoking status, menopausal status, stage, and nodal status) were utilized to 
determine relationships between gene expression and clinical parameters. 
Microarray analyses were performed on LCM procured carcinoma cells from 247 
breast cancer tissue biopsies as described. (Ma et al., 2003; J. L. Wittliff, 2010) 









Patient Characteristics n 
Median Age (range) 
 59 years (21-89.5) 247 
Median Observation Time (range) 
 65 months (3-155) 247 
Race 
 White 211 
 Black 34 
 Other 2 
Histology 
 Invasive ductal carcinoma 193 
 Lobular carcinoma 15 
 Medullary carcinoma 8 
 Other/Unknown 31 
Median Tumor Size (range) 
 27 mm (3-100) 218 
Stage 
 0 3 
 1 60 
 2A 85 
 2B 55 
 3A 22 
 3B 13 
 4 4 
 Unknown 5 
Grade 
 1 14 
 2 70 
 3 94 
 4 1 
 Unknown 68 
Estrogen Receptor Status 
 Negative 98 
 Positive 151 
Lymph Node Status 
 Negative 125 
 Positive 102 
 Unknown 20 
Recurrence Status 
 Yes 98 
 No 146 
 Never disease-free 3 
 
Table 1. Summary of Patient Characteristics in Microarray Database 
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Gene Expression Analyses  
Levels of mRNA expression were analyzed by microarray and qPCR 
according to the protocols described in publications of previous investigators with 
Dr. Wittliff after isolation and the quality of RNA was evaluated with Agilent RNA 
6000 Nano Kits and the BioanalyzerTM Instrument (Agilent Technologies, Palo Alto, 
CA) (Sarah A Andres et al., 2015; Andres et al., 2013; Andres & Wittliff, 2011, 
2012; Kerr II & Wittliff, 2011). Relative gene expression levels were determined 
from qPCR with the ΔΔCt method using ACTB for normalization and Universal 
Human Reference RNA (Stratagene, La Jolla, CA) as the calibrator. 
Preliminary Gene Selection 
An exhaustive inquiry of prevalent literature revealed 63 peptide/protein 
hormones and 82 cognate receptor proteins as shown in the second box of Figure 
1 flow diagram. (Greenspan et al., 1997; Norman & Litwack, 1997) There are a 
number of peptide/protein hormones that have been reported to associate with 
multiple receptor proteins. For example, somatostatin (SST) is known to bind with 
five receptor isoforms – somatostatin receptor 1 (SSTR1), somatostatin receptor 2 
(SSTR2), somatostatin receptor 3 (SSTR3), somatostatin receptor 4 (SSTR4) and 
somatostatin receptor 5 (SSTR5). (Hoyer et al., 1995) Similarly, receptors may pair 
with more than a single peptide/protein hormone. For instance, Spier and de Lecea 
(2000) demonstrated that another hormone, cortistatin (CORT), was also 
recognized by each of the five somatostatin receptors described above. Among 
the extensive repository of expression levels for ~22,000 genes in our microarray 
results of LCM-procured carcinoma cells, those genes for 61 hormones and 81 
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receptors were identified as candidates for analyses. The 247 tissue biopsies from 
patients with primary invasive ductal carcinoma served as the principal study 
population. 
Univariate Cox Regression  
Univariate Cox regression was performed on each of the 142 gene 
candidates using their relative expression levels as described in the third step of 
the flow diagram (Figure 1). Both Progression Free Survival (PFS) and Over-All 
Survival (OS) were analyzed as clinical outcomes for each gene. Univariate Cox 
models employed relative gene expression values as a single covariate (i.e., SST) 
and investigated the extent to which expression levels of a single gene in the cohort 
predicted the risk of recurrence of breast cancer (PFS) or succumbing to that 
disease (OS). 
The general formula for the hazard function of a Cox proportional hazard 
model is as follows: ℎ(𝑡) = ℎ0(𝑡) exp (𝛽1𝑥1 + 𝛽2𝑥2 + ⋯+ 𝛽𝑝𝑥𝑝). (Bradburn, Clark, 
Love, & Altman, 2003) The hazard function (ℎ(𝑡)) is time dependent, which 
changes over time along with the baseline hazard (ℎ0(𝑡)). The baseline hazard 
measures the risk when all covariates (𝑥1, 𝑥2 … 𝑥𝑝) are equal to 0. Although the 
baseline hazard may change over time, one of the assumptions for Cox models is 
that the hazard for different subsets of the population will be proportional to the 
baseline hazard at all times. The beta coefficients (𝛽1,𝛽2 …𝛽𝑝), which link the 
covariates to the hazard at time t, are determined by maximizing the partial 
likelihood function associated with the model. Covariates are variables such as 
13 
 
relative gene expression values for each of the hormones or their receptors. 
Univariate Cox regressions have a single beta coefficient calculated for a single 
covariate as shown here:  ℎ(𝑡) = ℎ0(𝑡) exp (𝛽1𝑥1). 
Hazard ratios (HR) were derived from univariate Cox regression models by 
the exponentiation of 𝛽1 and calculated for each of the 142 candidate genes. A 
hazard ratio for these models compares hazards (or risks for the clinical outcome 
being measured) at two different levels of gene expression. (Klein & 
Moeschberger, 2003) Since relative gene expression values are continuous 
covariates, the HR compares the hazard at any relative gene expression value to 
the hazard at a one unit level increase in relative gene expression. 
𝐻𝑅 = 
ℎ0(𝑡) exp (𝛽1(𝑥1 + 1))
ℎ0(𝑡) exp (𝛽1𝑥1)
= exp (𝛽1) 
An HR of greater than one represents an increase in risk, whereas a value of less 
than one represents a decrease in risk. An HR equal to one represents no 
difference in risk.  
  Each of the statistical computations was performed with R version 3.2.3. 
The commands coxph and cox.zph in the R package survival (Therneau, 2013) 
were used to calculate all univariate and multivariate Cox regressions and to 
validate the assumption of proportionality in significant genes. Cox regression p-
values were adjusted for multiple comparisons using the Benjamini & Hochberg 
method (Benjamini & Hochberg, 1995) with 0.30 “discovery” cutoff. Relative gene 
expression levels determined with LCM- procured carcinoma cells from 247 
patients were divided into groups expressing values that were above and below 
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the median for each gene candidate. These two groups of results were analyzed 
in Kaplan-Meier (KM) plots using the commands plot and survfit. The survdiff 
command performed a log-rank test comparing survival times between the two 
groups. 
Influence of Estrogen Receptor (ER) and Progestin Receptor (PR) Status on Gene 
Expression Levels 
Measurements of the protein biomarkers, ER and PR, have significant 
importance in predicting clinical outcomes of breast cancer patients such as risk 
of recurrence and over-all survival. (Fisher et al., 1987; Fisher et al., 1983; Fisher 
et al., 1981; Fleisher et al., 2002; Hammond et al., 2010; J. Wittliff et al., 1998) For 
example, patients with breast cancers exhibiting both ER and PR are reported to 
have a better prognosis and are candidates for anti-hormone therapy compared to 
those with ER and PR negative breast cancers. (Fisher et al., 1987; Fisher et al., 
2001; Fisher et al., 1981) This is thought to be due in part, to the observation that 
ER, when complexed with its native ligand, estradiol-17 B or an estrogen mimic 
(e.g., Tamoxifen), stimulates the production of PR. (Cormier, Wolf, & Jordan, 1989) 
Comprehensive clinical trials of breast cancer patients treated with Tamoxifen, 
such as those of the NSABP support this conclusion. (Fisher et al., 1987; Fisher 
et al., 1983; Fisher et al., 1981) 
 Patients were categorized into the breast cancer subsets based on the ER 
and PR protein status of the tissue biopsy. Patients were also stratified according 
to carcinoma cells exhibiting one of the four combinations of the two protein 
biomarkers, either ER+/PR+, ER+/PR-, ER-/PR+ or ER-/PR-. Univariate Cox 
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regression was first performed for patients with cancers stratified by each protein 
status, ER+, ER-, PR+ and PR-. Then patients were evaluated according to one 
of the four possible combinations of ER and PR (e.g., ER+/PR+, ER+/PR-, ER-
/PR+ or ER-/PR-) exhibited by their carcinoma cells with each of the 142 gene 
candidates. Kaplan-Meier plots were constructed for each gene using the various 
subsets of ER and PR. Box plots were constructed according to receptor status for 
each of the 142 candidate genes using the R command boxplot. The boxplots 
displayed the relative gene expression in the LCM-procured carcinoma cells for 
patients bifurcated by ER and PR status. The null hypotheses that the two groups 
come from identical populations was tested using the R command wilcox.test. The 
R command employed an unpaired independent two-sample Mann-Whitley-
Wilcoxon test by comparing ER+ to ER- groups and PR+ to PR- groups of breast 
cancers.  
Results 
Univariate Cox Regression of PFS and OS without Regard to ER and PR Status 
From univariate Cox regression for PFS, expression levels of fifteen genes 
for peptide/protein hormones and nineteen receptors showed significance at the 
adjusted p-value of <0.30 (Table 2). Noteworthy among the findings, the 
expression of POMC, whose mRNA transcript is quite large containing the 
sequences for a number of hormones, exhibited the highest statistical significance. 
(Lee et al., 2006) POMC had a HR of 1.72, which can be interpreted as patients 
with breast carcinomas expressing this gene at one unit higher have a 72% 
increase in risk of recurrence of metastatic breast cancer. The results obtained for 
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SST and SSTR1 are of particular interest because they are a hormone-cognate 
receptor pair, which appeared among the top five genes for univariate Cox 
regression for PFS. 
From univariate Cox regression for OS, expression levels of seven genes 
for peptide/protein hormones and ten receptor genes showed significance at the 
adjusted p-value of <0.30 (Table 3). Interestingly, expression of POMC gene 
related to breast cancer OS mirrored the highest statistical significance observed 
when PFS was calculated. All seventeen significant genes related to OS exhibited 
significant relationships with PFS. Also, the hormone-receptor pair POMC and 
MC5R exhibited statistical significance individually for univariate Cox regression 
for OS. 
Univariate Cox Regression of PFS and OS According to ER Status 
Using gene expression levels from 146 ER+ breast cancer carcinomas, 
univariate Cox regression determined that two peptide/protein hormones, SST and 
renin (REN), exhibited significant mRNA expression levels related to PFS and one 
receptor (SSTR2) was related to OS (Table 4). SST reappeared as significant for 
predicting PFS as it did for predicting PFS without regards to hormone receptor 
status. SSTR2, a cognate receptor for SST, exhibited significance for OS and will 
reappear in our molecular signature for ER+ breast cancers. Also showing 
significance for PFS is REN, which is normally produced in the kidneys when 
intrarenal blood pressure drops. The inhibition of REN has been demonstrated to 
mitigate angiogenesis, the production of new blood vessels. (Rodrigues-Ferreira 
& Nahmias, 2015). Cancer cells need more blood supply to provide them with the 
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nutrients to grow faster. The HR of REN is 2.93 meaning that cancers with higher 
























Gene Symbol β HR 95% CI (HR) adj. p 
POMC 0.54 1.72 (1.37,2.15) <0.001 
CALCR 0.44 1.56 (1.21,2.01) 0.03 
SST 0.55 1.73 (1.27,2.35) 0.03 
IGF1R.clone -0.17 0.84 (0.76,0.94) 0.05 
SSTR1 0.65 1.91 (1.28,2.84) 0.05 
TMSB15A 0.14 1.16 (1.05,1.27) 0.07 
PPY 0.93 2.55 (1.32,4.92) 0.10 
CRH 0.55 1.73 (1.18,2.54) 0.10 
SSTR3 0.97 2.64 (1.28,5.46) 0.13 
REN 0.61 1.85 (1.16,2.93) 0.13 
TMSB10 0.4 1.49 (1.1,2.02) 0.13 
ACVR2B 0.35 1.42 (1.08,1.86) 0.14 
ACVR2A 0.29 1.34 (1.06,1.7) 0.16 
PRL 0.32 1.38 (1.06,1.79) 0.16 
VIPR1 -0.26 0.77 (0.62,0.96) 0.18 
NPY1R -0.16 0.85 (0.74,0.98) 0.21 
SCT 0.58 1.79 (1.08,2.97) 0.21 
NPY6R -0.99 0.37 (0.15,0.9) 0.22 
INSR.AL365454 -0.25 0.78 (0.61,0.99) 0.23 
ACVR1 -0.27 0.76 (0.58,1) 0.23 
ACVR1B 0.25 1.29 (1.01,1.65) 0.23 
RLN1 -0.21 0.81 (0.66,0.99) 0.23 
RXFP3 1.2 3.32 (1.07,10.27) 0.23 
MC5R 0.6 1.83 (1.02,3.29) 0.23 
GHR 0.4 1.5 (1.02,2.2) 0.23 
AVPR2 0.75 2.11 (1.04,4.28) 0.23 
PTH -1.28 0.28 (0.08,0.98) 0.23 
EDN1 0.37 1.45 (1.03,2.05) 0.23 
GHSR -1.07 0.34 (0.13,0.94) 0.23 
RLN2 -0.13 0.88 (0.77,1) 0.23 
AGTRAP -0.31 0.73 (0.53,1.01) 0.27 
VIPR2 -0.1 0.91 (0.82,1) 0.27 
AVPR1A 0.88 2.41 (0.95,6.11) 0.28 
GAL 0.11 1.12 (0.99,1.26) 0.30 
     
Table 2. Summary of Genes with Expression Levels Associated with PFS. As described 
in Methods and Materials, expression levels of the 142 candidate genes were 




Gene Symbol β HR 95% CI (HR) adj. p 
POMC 0.52 1.68 (1.34,2.1) <0.001 
CALCR 0.45 1.57 (1.19,2.08) 0.08 
TMSB15A 0.18 1.19 (1.07,1.33) 0.08 
IGF1R.clone -0.17 0.85 (0.75,0.96) 0.16 
SSTR3 1.1 3.01 (1.34,6.76) 0.16 
SCT 0.79 2.21 (1.27,3.83) 0.16 
NPY6R -1.36 0.26 (0.09,0.71) 0.16 
TMSB10 0.45 1.57 (1.12,2.2) 0.16 
ACVR2A 0.35 1.42 (1.08,1.86) 0.19 
PPY 0.87 2.38 (1.15,4.93) 0.26 
PTH -1.77 0.17 (0.04,0.77) 0.26 
NPY1R -0.2 0.82 (0.69,0.97) 0.26 
MC5R 0.72 2.06 (1.07,3.97) 0.28 
VIPR1 -0.27 0.76 (0.59,0.98) 0.28 
VIPR2 -0.13 0.88 (0.78,0.99) 0.28 
EDN1 0.44 1.56 (1.05,2.3) 0.28 
GHSR -1.34 0.26 (0.08,0.87) 0.28 
     
Table 3. Summary of Genes with Expression Levels Associated with OS. As described in 
Methods and Materials, expression levels of the 142 candidate genes were 
determined using LCM-procured cells from 247 breast cancer biopsies. 
 
Using gene expression levels from 101 ER- breast cancer carcinomas, 
univariate Cox regression determined that mRNA levels of four genes for 
peptide/protein hormones and two receptor genes were correlated with a 
significant for predicting PFS and four genes for peptide/protein hormones 
predicted OS (Table 5). The gene expression levels of POMC were significant for 
predicting PFS and OS for ER- cancers similarly to our observation for predicting 
PFS and OS without regard to receptor status. CALCR, POMC, GH1 and PRL 
were significant for PFS and will reappear in our molecular signature for ER- 
cancers. Growth hormone (GH1) is typically produced in the pituitary gland 
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regulated by GHRH and SST from the hypothalamus. Models with SST and GHRH 
could be performed in future studies to see if the cancer cells may be controlling 
levels of GH1 by autocrine means. 
Univariate Cox Regression of PFS and OS according to PR status 
Using gene expression levels from 151 PR+ breast cancer carcinomas, 
univariate Cox regression determined that one peptide/protein hormone, thymosin 
β10 (TMSB10), exhibited significance for predicting PFS and three peptide/protein 
hormones, CALCA, TMSB10 and POMC, were significant for predicting OS (Table 
6). TMSB10 was first discovered in the thymus but is made throughout the body. 
TMSB10 has been shown to be overexpressed in lung and pancreatic cancer and 
even targeted for therapy. (Alldinger et al., 2005; Langevin, Kratzke, & Kelsey, 
2015) Are the mechanisms that cause TMSB10 to be overexpressed in lung and 
pancreatic cancers somehow related to breast cancers that exhibit high levels of 
PR but not necessarily ER? Interestingly, POMC is significant for OS but not PFS 
in a sex hormone positive (PR+) subtype. Could early deaths from patients who 










A. PFS ER+     
Gene Symbol β HR 95% CI (HR) adj. p 
SST 0.73 2.08 (1.28,3.39) 0.23 
REN 1.08 2.93 (1.47,5.85) 0.23 
     
B. OS ER+     
Gene Symbol β HR 95% CI (HR) adj. p 
SSTR2 0.28 1.32 (1.11,1.57) 0.27 
     
Table 4. Summary of Genes with Expression Levels Correlating either with PFS (A) or 
OS (B) for 146 ER+ Breast Carcinomas. As described in Methods and Materials, 
expression levels of 142 candidate genes were determined using LCM-procured cells 




A. PFS ER-     
Gene Symbol β HR 95% CI (HR) adj. p 
CALCR 0.43 1.53 (1.15,2.04) 0.16 
POMC 0.4 1.49 (1.17,1.9) 0.16 
GH1 -0.76 0.47 (0.28,0.79) 0.16 
PRL 0.58 1.79 (1.18,2.71) 0.16 
AVPR1A 1.83 6.23 (1.81,21.4) 0.16 
SCT 0.8 2.24 (1.19,4.2) 0.29 
     
B. OS ER-     
Gene Symbol β HR 95% CI (HR) adj. p 
POMC 0.37 1.45 (1.13,1.87) 0.28 
GH1 -0.84 0.43 (0.24,0.79) 0.28 
PRL 0.54 1.72 (1.15,2.56) 0.28 
SCT 0.94 2.55 (1.33,4.88) 0.28 
     
Table 5. Summary of Genes with Expression Levels Correlating either with PFS (A) or 
OS (B) for 101 ER- Breast Carcinomas. As described in Methods and Materials, 
expression levels of 142 candidate genes were determined using LCM-procured cells 





A. PFS PR+     
Gene Symbol β HR 95% CI (HR) adj. p 
TMSB10 0.97 2.63 (1.56,4.44) 0.04 
     
B. OS PR+     
Gene Symbol β HR 95% CI (HR) adj. p 
CALCA 0.38 1.46 (1.14,1.85) 0.23 
TMSB10 0.87 2.39 (1.34,4.27) 0.23 
POMC 0.86 2.36 (1.29,4.34) 0.27 
     
Table 6. Summary of Genes with Expression Levels Associated either with PFS (A) or 
OS (B) for 151 PR+ Breast Carcinomas. As described in Methods and Materials, 
expression levels of 142 candidate genes were determined using LCM-procured cells 
from 247 breast cancer biopsies. 
 
Using gene expression levels from 96 PR- breast cancer carcinomas, 
univariate Cox regression determined that five genes for peptide/protein hormones 
and five receptor genes were significant for predicting PFS. No genes were found 
to be significant after adjusting p-values for multiple comparisons (Table 7). 
CALCR, POMC and PRL are shown to have an association with PFS for PR- 
breast cancer carcinomas and were also associated with ER- breast cancer 
carcinomas. These three genes will be common to two molecular signatures. Since 
1995, researchers have known about the ability of breast cancer cells to secrete 
active forms prolactin (PRL) possibly through autocrine mechanisms, although 
paracrine mechanisms could not be ruled out. (Ginsburg & Vonderhaar, 1995) We 
will look at the relationship between PRL and its cognate receptor PRLR in Chapter 
Three but further study could be performed on the statistical interactions of PRL 





PFS PR-     
Gene Symbol β HR 95% CI (HR) adj. p 
CALCR 0.56 1.75 (1.3,2.37) 0.04 
POMC 0.43 1.54 (1.18,2.01) 0.11 
SST 0.71 2.03 (1.26,3.26) 0.14 
SSTR1 0.67 1.96 (1.23,3.13) 0.14 
CRH 0.62 1.86 (1.21,2.87) 0.14 
AVPR2 1.18 3.25 (1.39,7.57) 0.15 
AVPR1A 1.74 5.71 (1.51,21.57) 0.20 
ACVR1 -0.4 0.67 (0.48,0.93) 0.30 
PRL 0.42 1.52 (1.07,2.16) 0.30 
PTH -2.31 0.1 (0.01,0.71) 0.30 
     
Table 7. Summary of Genes with Expression Levels Associated with PFS for 96 PR- 
Breast Carcinomas. As described in Methods and Materials, expression levels of 142 
candidate genes were determined using LCM-procured cells from 247 breast cancer 
biopsies. 
 
Univariate Cox Regression of PFS and OS according to ER/PR status 
 Since both the status of ER and PR are considered in the clinical setting 
when assessing a patient’s risk of recurrence and selection of a therapeutic agent, 
these studies utilized the results of clinical determinations of the steroid hormone 
receptors. (Fisher et al., 1987; Fisher et al., 1983; Fisher et al., 1981; Fleisher et 
al., 2002; Hammond et al., 2010; J. Wittliff et al., 1998) The analyses described 
include the four combinations ER+/PR+, ER+/PR-, ER-/PR+ and ER-/PR- status 
of each of the breast cancer surgical biopsies submitted for ER and PR protein 
analyses. In general, a patient with a breast carcinoma determined to be ER+/PR+ 
exhibits the best prognosis compared to the patients with cancers exhibiting the 
other combinations. Best prognosis implies that the patient is expected to have a 
lower risk of breast cancer recurrence compared with patients with cancer biopsies 
exhibiting the other three combinations of ER and PR. A patient with ER-/PR- 
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breast carcinoma exhibits the worst prognosis compared to that the other patients. 
In addition, patients with ER-/PR- tumors are not candidates for hormone-receptor 
protein based therapies such as tamoxifen. (Fisher et al., 1987; Hammond et al., 
2010; Kerr II & Wittliff, 2011) 
Since our goal is to decipher molecular signature for predicting breast 
cancer outcomes, we undertook the following analyses. Using gene expression 
levels from 118 ER+/PR+ breast cancer carcinomas, univariate Cox regression 
determined that the receptor SSTR2 exhibited significance for predicting OS 
(Table 8). Using gene expression levels determined from LCM-procured of 28 
ER+/PR- breast cancer carcinomas, univariate Cox regression determined that 
one peptide/protein hormone, EPO, and two genes of receptors, CALCR and 
ACVR1B, had significance for predicting PFS (Table 9). However since this sample 
group only contained 28 patients, caution must be taken in the interpretation of 
these analyses. We noted that erythropoietin, EPO had not appeared in any of the 
gene subsets detected thus far. Furthermore CALCR has been significant for 
predicting PFS of ER+/PR-, PR-, ER- breast cancer patients and for predicting 
PFS and OS without regard to receptor status.  
The expression of ER-/PR+ protein biomarkers in a breast cancer is 
infrequently observed and since the action of ER is known to provoke the 
production of PR, its appearance is the focus of research. (Andres & Wittliff, 2012; 
Fleisher et al., 2002; J. Wittliff et al., 1998) Unfortunately, using gene expression 
levels from 33 ER-/PR+ breast cancer carcinomas, univariate Cox regression 
determined no genes of significance after adjusting p-values for multiple 
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comparisons. This may be due to a small sample size. A few significant findings 
from unadjusted p-values could have been novel in their implications. 
Breast carcinoma biopsies that lack both ER and PR protein (ER-/PR-) are 
widely known to correlate with poor prognosis of breast cancer patients and their 
lack of response to anti-hormone therapies. (Andres & Wittliff, 2012; Fleisher et 
al., 2002; J. Wittliff et al., 1998) Using gene expression levels determined by 
microarray from LCM-procured carcinoma cells of 68 ER-/PR- breast cancer 
carcinomas, univariate Cox regression determined mRNA expression levels of two 
peptide/protein hormones, POMC and PRL, significant for predicting PFS (Table 
10). The genes for PRL and POMC appear later in our molecular signature for ER- 
breast carcinomas. 
Analyses of Clinical Relevance using Kaplan-Meier Plots 
 Due to the numerous genes exhibiting significance for predicting PFS and 
OS of breast cancer for each category of receptor status, a representative sample 
of Kaplan-Meier plots has been presented. (Rich et al., 2010) Without regards to 
ER/PR status, IGF1R.clone and GAL genes showed significant differentiation for 
predicting PFS and OS between cancers that expressed the gene above the 
median versus compared to those that expressed the gene below the median. The 
median is taken as a first discriminator in this thesis, however later analyses for 
the development of manuscripts will also derive outcomes as a function of 
quartiles. TMSB10 expression was significant for predicting PFS while that of 
activin A receptor type IIA, ACVR2A, was significant for predicting OS. The risk of 
recurrence and survivorship was worse for patients whose tumors expressed 
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IGF1R.clone mRNA below the median and GAL, TMSB10 and ACVR2A mRNA 
expression levels that were above the median.  
 For ER+ cancers, SST gene expression showed a significant differentiation 
for predicting PFS and a poor prognosis for patients whose lesions expressed the 
gene above the median. SSTR2 was significant for predicting OS with a poor 
prognosis for patients whose tumors expressed the gene above the median. For 
ER- carcinomas, expression of growth hormone, GH1, predicted both PFS and OS 
that was highly statistically significant with a poor prognosis for those whose breast 
cancers expressed GH1 below the median. 
 For PR+ cancers, glycoprotein hormone alpha polypeptide, CGA, showed 
a significant differentiation for predicting PFS while that of endothelin, EDN1, 
showed significance for predicting OS using Kaplan-Meier plots.  Patients 
expressing CGA and EDN1 above the median were correlated with a worse 
prognosis compared to patients expressing these genes at levels below the 
median. For PR- cancers, arginine vasopressin receptor 2, AVPR2, significantly 
differentiated patients above and below the median for PFS and GH1 significantly 
differentiated patients above and below the median for OS. Patients with breast 
cancers expressing CGA above the median and patients with breast cancers 
expressing GH1 below the median had a worse prognosis. 
 Examination of ER+/PR+ carcinomas revealed that CALCA significantly 
differentiated patient outcome for PFS while SSTR2 showed significance for 
predicting OS.  Patients expressing CALCA and SSTR2 above the median were 
correlated with a worse prognosis than those with gene expression levels below 
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the median. The most significant findings from the Kaplan-Meier plots were 
revealed in carcinoma cells classified as ER-/PR-, the biomarker status that is 
related to the worse prognosis among the four combinations. When ER-/PR- 
cancers were examined, GH1 expression was highly significant for predicting PFS 
and OS with those whose lesions expressed GH1 below the median having the 
highest risk of recurrence and survivorship. 
Evaluation of Influence of Steroid Hormone Receptor Status using Boxplots 
  One of the goals of this study was to determine if there were candidate 
genes whose expression was related to the expression levels of either ER or PR 
protein. Such relationships would suggest that steroid hormone action may be 
related to the expression of certain peptide/protein hormone genes and the genes 
for their receptors. Due to the magnitude of the analyses and results for the 142 
candidate genes only representative boxplots that showed the greatest statistical 
significance are displayed. Considering influence of ER, the relative gene 
expression of receptor activity modifying protein 2 (RAMP2), IGF1R, IGF1R.clone, 
angiotensin II receptor, type 1 (AGTR1) and thyrotropin-releasing hormone (TRH) 
were significantly higher levels in ER+ carcinoma cells compared to their ER- 
counterparts. The relative gene expression of ACVR2A and GAL in ER- cancers 
was significantly higher than observed in ER+ cancer cells. The relative gene 
expression of AGTR1 and IGF1R.clone in PR+ breast cancers was expressed at 
a significantly higher level than their expression levels in PR- carcinoma cells. A 
boxplot (results not shown) revealed that GH1 expression was significant for both 
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ER and PR. GH1 was overexpressed in ER- and PR- subgroups compared to ER+ 
and PR+ carcinomas.  
 
OS ER+/PR+     
Gene Symbol β HR 95% CI (HR) adj. p 
SSTR2 0.34 1.4 (1.14,1.72) 0.16 
     
Table 8. Summary of Genes with Expression Levels Associated with OS for 118 
ER+/PR+ Breast Carcinomas. As described in Methods and Materials, expression levels 
of 142 candidate genes were determined using LCM-procured cells from 247 breast 
cancer biopsies. 
 
PFS ER+/PR-     
Gene Symbol β HR 95% CI (HR) adj. p 
CALCR 1.11 3.03 (1.46,6.29) 0.15 
ACVR1B 1.16 3.2 (1.48,6.95) 0.15 
EPO 0.61 1.85 (1.25,2.74) 0.15 
     
     
Table 9. Summary of Genes with Expression Levels Associated with PFS for 28 ER+/PR- 
Breast Carcinomas. As described in Methods and Materials, expression levels of 142 
candidate genes were determined using LCM-procured cells from 247 breast cancer 
biopsies. 
 
PFS ER-/PR-     
Gene Symbol β HR 95% CI (HR) adj. p 
POMC 0.4 1.49 (1.14,1.94) 0.25 
PRL 0.63 1.88 (1.23,2.86) 0.25 
     
Table 10. Summary of Genes with Expression Levels Associated with PFS for 68 ER-
/PR- Breast Carcinomas. As described in Methods and Materials, expression levels of 
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Figure 2 Representative Kaplan-Meier Plots Comparing Above and Below the Median 
Relative Gene Expression (1). Without regards toward receptor status, IGF1R.clone (A), 
TMSB10 (B) and GAL (C) displayed significance difference between groups for PFS, while 
IGF1R.clone (D), ACVR2A (E) and GAL (F) were significant for OS. For ER+ tumors, SST (G) 
displayed significance difference between groups for PFS, while SSTR2 (H) was 
significant for OS. For ER- tumors, GH1 (I) displayed significance difference between 
groups for PFS. 
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Figure 3. Representative Kaplan-Meier Plots Comparing Above and Below the Median 
Relative Gene Expression (2). For ER- tumors, GH1 (A) displayed significance difference 
between groups for OS. For PR+ tumors, CGA (B) displayed significance difference 
between groups for PFS, while EDN1 (C) was significant for OS. For PR- tumors, AVPR2 
(D) displayed significance difference between groups for PFS, while GH1 (E) was 
significant for OS. For ER+/PR+ tumors, CALCA (F) displayed significance difference 
between groups for PFS, while SSTR2 (G) was significant for OS. For ER-/PR- tumors, GH1 
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Figure 4. Representative Boxplots Comparing Distributions of Relative Gene Expressions 
by Receptor Status. The gene expression of RAMP2 (A), IGF1R (B), IGF1R.clone (C), 
AGTR1 (D) and TRH (E) in ER+ tumors was expressed at a significantly higher level than 
ER- tumors. The gene expression of ACVR2A (F) and GAL (G) in ER- tumors was 
expressed at a significantly higher level than ER+ tumors. The gene expression of AGTR1 






The use of these comprehensive, de-identified databases containing a 
variety of molecular biological results complemented by characteristics of the 
breast carcinoma and the clinical outcome of the patient have allowed the 
exploration of original questions and hypotheses related to biomarkers of clinical 
relevance in breast carcinoma management. These matchless resources 
combined with a range of statistical tests, bioinformatics tools and novel, 
sophisticated software have given me a unique opportunity to learn new 
approaches and integrate results of complex molecular assays with clinical 
outcomes. As a result, we have uncovered a gold mine of potential 
interrelationships between gene expression/ protein biomarker levels and breast 
carcinoma behavior. 
In support of our approach outlined in Figure 1 (Flow Diagram), the integrity 
of the databases mined in these investigations is based on the following facts. 
Firstly, each of the tissue biopsies of breast cancer was collected in Pathology 
Departments of hospitals utilizing standardized protocols for specimen handling 
developed by Dr. Wittliff and then processed and stored deep frozen under 
stringent conditions established in the Hormone Receptor Laboratory. The HRL 
holds both CLIA and Commonwealth of Kentucky licenses as a clinical laboratory.  
Secondly, each of the specimens in the Biorepository and results 
accumulated in the comprehensive databases were de-identified under approval 
of the Institutional Review Board (IRB) of the University of Louisville. Next, using 
these frozen biopsy specimens, tissue sections were uniformly processed and only 
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breast carcinoma cells were Laser Capture Microdissected in a non-destructive 
fashion using protocols established by Dr. Wittliff and collaborators. (J. L. Wittliff, 
2010) The extraction and purification of RNA from LCM-procured cells as well as 
RNA amplification and microarray analyses of gene expression were performed in 
well controlled, highly reproducible assays. This is documented by acceptance of 
various publications (Andres et al., 2013; Metzler et al., 2015; J. L. Wittliff, 2010) 
as well as acceptance of patent applications filed describing molecular profiling of 
breast cancers (JLW & Arcturus patent applications).  
Lastly, microarray results of expression of certain genes were validated by 
qPCR (Andres & Wittliff, 2011, 2012; Kerr II & Wittliff, 2011) and determinations of 
ER and PR protein levels in tissue biopsies were performed with FDA-approved 
kits that gave quantitative results. My Co-mentor, Dr. Wittliff developed the radio 
ligand-binding assays which not only measured the levels of the active ER and PR 
proteins but gave affinities of the association of the sex hormone receptors for their 
ligands which were radioactively labeled. Thus the databases and statistical 
approaches that I have used to investigate expression of genes for 142 
peptide/protein hormone and their receptor proteins in breast carcinoma cells to 
derive clinically useful molecular signatures have great reliability.  
POMC was the most significant gene for univariate Cox regression without 
regard to receptor status. POMC is a 241 amino acid long polypeptide typically 
produced in the pituitary gland and is cleaved at various sites to make a number 
of other proteins including adrenocorticotropic hormone (ACTH) and β-lipotropin. 
(Kaushal & Sinha, 2015) POMC is secreted in response to corticotropin-releasing 
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hormone (CRH), a gene also significant for univariate Cox regression. ACTH is 
necessary for steroidogenesis, which converts cholesterol into steroids such as 
progesterone, estrogen and cortisol (an immunosuppressant). (Hanukoglu, 1992) 
The gene pairs POMC & MC5R, SST & SSTR1, SST & SSTR3, RLN1 & RXFP3 
and RLN2 & RXFP3 had both genes individually among the univariate significant 
genes.  
Twelve of the 34 genes significant for univariate Cox regression for PFS 
without regard to receptor status were also significant for the log-rank test derived 
for Kaplan-Meier plots. Of the twelve genes showing significance for univariate 
Cox regression and Kaplan-Meier plots, POMC, VIPR1, RLN1, ACVR2A, SST and 
CALCR will be in the 14-gene signature for predicting PFS as described in the flow 
diagram. (Figure 1) 
Nearly half the genes (67 of 142) had significantly different relative gene 
expressions for either ER+ versus ER- or PR+ versus PR- as shown by a 
representative sample of boxplots. An important question for these 67 genes is 
whether estrogen or progesterone is regulating them. The Kaplan-Meier plots 
without regards to receptor status provide some evidence for this question. Among 
the 22 significant genes for PFS or OS for Kaplan-Meier plots, thirteen are common 
to those significant for differences between ER and PR status expressed in the 
boxplots. The common genes are IGF1R.clone, AGTRAP, ACVR2A, RLN1, TRH, 
POMC, GH1, VIPR1, EDN1, GAL, GHSR, TMSB10 and TMSB15A. These genes 
are associated with the signaling pathways for estrogen or progesterone and 
require further investigation to discern the association. 
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Growth hormone (GH1), POMC and CALCR were highly significant for 
univariate Cox regression and Kaplan-Meier plots for ER- breast carcinomas and 
will be in the 9-gene signature for ER- cancers as described in the flow diagram. 
(Figure 1) Interestingly, the only gene that showed a protective effect as relative 
gene expression increases (negative beta coefficient) for PFS was GH1. GH1 is 
secreted in the pituitary gland and up regulated by growth hormone releasing 
hormone (GHRH) and down regulated by somatostatin in the hypothalamus. 
(Wagner et al., 2006) GH1 promotes insulin-like growth factor (IGF1) in the liver. 
IGF1 has been targeted in a pathway to regulate the metastasis of breast cancer. 
(Sachdev, 2008; Yang & Yee, 2012) There was no surprise to find IGF1 eventually 
show up in our 9-gene model for ER- breast cancers. Why does the increase in 
the expression of a gene, which promotes a gene in a known breast cancer 
metastasis pathway, has a protective effect against the progression of breast 
cancer?  
Clinically, cancers identified as ER-/PR- have the worst prognosis. Prolactin 
(PRL) was the most significant gene for PFS and OS for these cancers followed 
closely by GH1, POMC and CALCR, mentioned above for ER- cancers. Elevated 
circulating PRL has been shown to increase the risk of breast cancer in situ. (Tikk 
et al., 2015) PRL and prolactin receptor will appear in our 9-gene molecular 
signature for ER- breast cancers. Before modeling any molecular signatures, we 
need to evaluate how these hormones and receptors may be affecting one another 
statistically. Collectively, these results lead us to look at various models and 





The analyses described in Chapter One using gene expression levels from 
LCM-procure breast carcinoma cells were expanded with various techniques for 
multivariate analyses as described in Figure 1 flow diagram. Cox regressions were 
computed for two variable models and models with an interaction term with gene 
expression results from the candidate peptide/protein hormones and their 
receptors. Least absolute shrinkage and selection operator (LASSO) was used to 
fit a model with each of the 142 candidate genes at one time to determine the 
relationship with prediction of risk of breast cancer recurrence.  
In Chapter Two, univariate Cox regression evaluated the expression of each 
gene’s influence on a breast cancer patient’s clinical outcome. A unique aspect to 
this study is the ability to examine a peptide/protein hormone and their cognate 
receptor/s as a combination and the manner in which these pairs of gene 
expressions may play a role in predicting DFS and OS. A novelty of our study is 
that we have discovered many primary breast carcinomas exhibit elevated levels 
of expression of numerous genes for peptide/protein hormones and their receptors 
which are known to regulate physiologic pathways. There is no biochemical 
interaction between mRNAs but the proteins they eventually encode definitely 
interact. The problem with measuring mRNA is that we cannot say with certainty 
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that they will be coded into proteins. The correlation is there but the cell may have 
mutations that fail to translate the mRNA into the protein. If we wanted to ensure 
the levels of protein match the levels of mRNA then we would need to do qPCR or 
other techniques that measure proteins in the cell. (Wu & Singh, 2012) Although 
there is no biological interaction/association between each of the mRNA molecules 
of a hormone and that of its receptor, a statistical interaction may be computed.  
Methods and Materials 
Multivariate Cox Regression 
Two types of Cox models were employed to evaluate the relationships 
between gene expression results for peptide/protein hormones and their cognate 
receptors with clinical outcomes. The first computes a two variable model 
(hormone + receptor) and the second model adds a third interaction term to the 
model. The two variable model has the form ℎ(𝑡) = ℎ0(𝑡) exp  (𝛽1𝑥1 + 𝛽2𝑥2) and 
the interaction model has the form ℎ(𝑡) = ℎ0(𝑡) exp (𝛽1𝑥1 + 𝛽2𝑥2 + 𝛽3𝑥1𝑥2). (Klein 
& Moeschberger, 1997) The expression of the hormone and receptor is 
represented by x1 and x2, respectively. The baseline hazard at time t is represented 
by h0(t) while the hazard at time t is represented by h(t). In a two-variable Cox 
model, the beta coefficient for the hormone reflects the weight for which the 
expression for the hormone’s gene has on the hazard function while controlling for 
the expression of the receptor gene. Likewise, the beta coefficient for the receptor 
gene expression reflects its weight on the hazard function while controlling for the 
gene expression of the hormone. These models provide the HR for cancers 
expressing a gene while accounting for the levels of the expression of its partner 
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gene. In the interaction model, if the beta coefficient for the interaction term is 
significant, then the gene expression results for the hormone and its receptor have 
a strong statistical dependence on each other. Hazard ratios for the hormone and 
receptor gene expression levels are conditioned on the level of its associated 
partner. The exponentiation of 𝛽3 represents the excess hazard from the statistical 
interaction of the gene expressions of the hormone and its cognate receptors. 
Multivariate Cox regression analyses were extended to all of the subsets of 
receptor status as discussed in Chapter Two Methods and Materials. Kaplan-Meier 
(KM) plots were constructed along with each pair with and without regards to 
ER/PR status to assess association with prediction of breast cancer recurrence. 
KM plots were constructed with four categories: above the median gene 
expression for both the hormone and receptor, below the median for both the 
hormone and receptor and the two discordant combinations.  
Least Absolute Shrinkage and Selection Operator  
With such a large number of genes (e.g., 142), stepwise selection methods 
to determine significant genes in a model are not feasible (Austin & Tu, 2004). An 
increase in the standard error of coefficients due to the multicollinearity of gene 
expression values may lead to type II errors – failure to reject a false hypothesis. 
An alternative method, Least Absolute Shrinkage and Selection Operator 
(LASSO), was used to evaluate each of the 142 candidate genes in primary breast 
carcinoma cells of 247 patients in models for DFS and OS. LASSO penalizes the 
size of β⃑  and removes genes whose coefficients are close to zero. The maximum 
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likelihood estimates β̂ are derived by maximizing the penalized Cox log partial 
likelihood with the form 𝑙(𝛽) − ∑ 𝜆|𝛽𝑗|
𝑝
𝑗=1 , where 𝑙 (𝛽) represents the standard log 
Cox log partial likelihood and λ is the shrinkage parameter. Using 10-fold cross-
validation to minimizing the mean square error determined the optimal value for λ 
(Andres et al., 2013). A larger λ corresponds to a larger penalty on the Cox log 
partial likelihood and thus removes more variables from the model alleviated the 
more predictive ability of overfitting a model. Further examination of the two clinical 
outcomes (PFS & OS) with combinations of biomarker profiles were assessed as 
well. The commands penalized and optL1 in the R package penalized were used 
to perform an optimized L1 penalty, “LASSO”, for a Cox model. (J. Goeman, 
Meijer, & Chaturvedi, 2014; J. J. Goeman, 2010) 
Results 
Multivariate Cox Regression with Interaction of PFS and OS without Regard to ER 
and PR Status of the Cancer Biopsy 
 For interaction models, the sign of the beta coefficient for the interaction 
term and its corresponding p-value are the most informative outputs from these 
types of Cox regressions. A negative beta coefficient reflects an antagonistic effect 
on the hazard, while a positive beta coefficient has a synergistic effect. For 
instance in Table 11, HCRT (orexin) and HCRTR2 (hypocretin receptor 2) 
exhibited a significant interaction term (adjusted p=0.23) for a false discovery rate 
cutoff of p<0.3 for OS with a positive beta coefficient (β=1.53) that indicates there 
is a significant increase in risk when expression levels of the two genes are 
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considered together. HRs for the main effects (i.e., hormone or receptor) of these 
Cox models are conditional HRs that depend upon the expression levels of the 
other gene in the model and are not shown for the sake of brevity. Table 1 shows 
the HR and 95% confidence interval for the HR of the interaction term and 
represents the excess risk from a synergistic effect or reductive risk from an 
antagonistic effect.  
OS     
Gene Symbol β HR 95% CI (HR) adj. p 
HCRT & HCRTR2 1.53 4.63 (1.75,12.23) 0.23 
     
     
Table 11. Summary of the Interaction Term for Hormone and Receptor Gene Pairs 
with Expression Levels Associated with OS without Regard to Receptor Status. As 
described in Methods and Materials, expression levels of 142 candidate genes were 
determined using LCM-procured cells from 247 breast cancer biopsies. 
 
Multivariate Cox Regression with Interaction of PFS and OS with Regard to ER 
and PR Status of the Cancer Biopsy 
 For ER+ cancers, two hormone-receptor pairs, INHA-ACVR2B and 
GNRH2-GNRHR, exhibited significance when associated with OS (Table 12). 
Interpretation of these interactions should be done with care. For example, inhibin 
(INHA) and activin A receptor, type IIB (ACVR2B) has an antagonistic effect on the 
overall hazard since the interaction beta coefficient (β3) is negative. Yet, the beta 
coefficients for the main effects (i.e., INHA (β1) and ACVR2B (β2)) are positive 
(β1=0.52, β2=1.00), which can be interpreted as an increase in the expression level 
of INHA or ACVR2B increases the risk of death (OS) at time t. In other words, the 
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overall hazard is a convolution of the increased risk from the levels of INHA and 
ACVR2B and the decreased risk from the statistical interaction of the two at these 
levels. INHA-ACVR2B and GNRH2-GNRHR would be candidates for further study 
to test signaling pathways for endocrine autonomy.       
OS Interaction ER+    
Gene Symbol β HR 95% CI (HR) adj. p 
INHA & ACVR2B -1.62 0.2 (0.08,0.51) 0.09 
GNRH2 & GNRHR 9.99 21907.54 (26.77,17930991) 0.20 
     
Table 12. Summary of the Interaction Term for Hormone and Receptor Gene Pairs 
with Expression Levels Associated with OS for 146 ER+ Breast Carcinomas. As 
described in Methods and Materials, expression levels of 142 candidate genes were 
determined using LCM-procured cells from 247 breast cancer biopsies. 
 
 For ER- cancers, Table 13 shows gene expression levels of five hormone-
receptor pairs exhibiting significance for interaction for OS.  The interaction term 
for HCRT-HCRTR2 was significant for ER- breast cancer and also significant for 
breast cancers without regard to receptor status. Interestingly, the hormone-
receptor pairs significant for interaction in ER+ cancers reappeared with different 
genes but from the same group. For example, INHA-ACVR2B was significant in 
ER+ breast cancers and inhibin beta C (INHBC) and activin receptor type IB 
(ACVR1B) was significant in ER- breast cancers. This is also similar for the 
hormone gonadotrophin, which expressed type II significant for ER+ cancers and 
type II significant for ER- cancers. Three out of the five pairs showing significance 
for ER- cancers typically produce their hormone in the hypothalamus and regulate 
a variety of other peptide/protein hormones. These three hormones, CRH, GNRH1 
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and HCRT, should be examined more closely with the hormones they regulate to 
verify any autocrine pathways in ER- breast cancers. 
OS Interaction ER-     
Gene Symbol β HR 95% CI (HR) adj. p 
IAPP & CALCR 3.93 50.99 (2.95,881.85) 0.20 
INHBC & ACVR1B 0.46 1.59 (1.15,2.2) 0.20 
CRH & CRHR1 -1.9 0.15 (0.04,0.53) 0.20 
GNRH1 & GNRHR 2.77 15.9 (2.29,110.59) 0.20 
HCRT & HCRTR2 1.5 4.47 (1.37,14.55) 0.30 
     
Table 13. Summary of the Interaction Term for Hormone and Receptor Gene Pairs 
with Expression Levels Associated with OS for 101 ER- Breast Carcinomas. As 
described in Methods and Materials, expression levels of 142 candidate genes were 
determined using LCM-procured cells from 247 breast cancer biopsies. 
 
 For PR+ cancers, six pairs of hormone-receptor combinations showed 
significance for OS (Table 14) Amylin (IAPP) and calcitonin receptor (CALCR) 
exhibited the largest effect size for statistical interaction for PR+ cancers and 
previously in ER- cancers. Because elevated levels of ER promote elevated levels 
of PR, one would not expect genes that are expressed in ER- cancers to be 
expressed in PR+ cancers. This anomaly should be investigated as a new finding 
in order to rule out as simple randomness. POMC was identified for the first time 







OS Interaction PR+     
Gene Symbol β HR 95% CI (HR) adj. p 
IAPP & CALCR 3.73 41.61 (2.68,645.8) 0.23 
RLN2 & RXFP1 0.64 1.91 (1.2,3.02) 0.23 
CGA & TSHR 0.27 1.31 (1.08,1.58) 0.23 
GHRH & GHRHR 0.58 1.79 (1.16,2.75) 0.23 
EDN1 & EDNRA -1.1 0.33 (0.14,0.78) 0.27 
POMC & MC5R 2.78 16.07 (1.69,153.35) 0.30 
     
Table 14. Summary of the Interaction Term for Hormone and Receptor Gene Pairs 
with Expression Levels Associated with OS for 151 PR+ Breast Carcinomas. As 
described in Methods and Materials, expression levels of 142 candidate genes were 
determined using LCM-procured cells from 247 breast cancer biopsies. 
 
 For LCM-procured breast carcinoma cells from PR- cancers, four hormone 
and receptor pairs revealed significance for an association for OS (Table 15). 
Orexin (HCRT) along with two of its cognate receptors, HCRTR1 and HCRTR2, 
synergistically increased the risk for their hazard functions. An interesting result is 
the significance of the pair cortistatin (CORT) and SSTR4 in ER- cancers. In ER- 
cancers, POMC and PRL are overexpressed with relative gene expression means 
of 0.38 and 0.24, respectively, while CORT and SSTR4 are under expressed with 
relative gene expression means of -0.2 and -0.1, respectively. CORT has been 
shown to have an inhibitory effect upon the production of POMC and PRL 
(Córdoba-Chacón et al., 2011). If elevated gene expressions of POMC and/or PRL 
in ER- cancer cells are in a signally pathway to cause progression or death from 
the disease, then a therapeutic treatment for ER- cancers may be to find ways to 




OS Interaction PR-     
Gene Symbol β HR 95% CI (HR) adj. p 
HCRT & HCRTR2 1.87 6.48 (2.09,20.07) 0.14 
CRH & CRHR1 -1.79 0.17 (0.04,0.63) 0.24 
HCRT & HCRTR1 2.31 10.11 (1.81,56.46) 0.24 
CORT & SSTR4 1.14 3.14 (1.38,7.12) 0.24 
     
     
     
Table 15. Summary of the Interaction Term for Hormone and Receptor Gene Pairs 
with Expression Levels Associated with OS for 96 PR- Breast Carcinomas. As described 
in Methods and Materials, expression levels of 142 candidate genes were determined 
using LCM-procured cells from 247 breast cancer biopsies. 
 
 For ER+/PR+ cancers, three pairs of hormone-receptor combinations 
showed significance for estimating the relationship with PFS (Table 16). All three 
pairs typically produce their hormones in the anterior pituitary gland. The hormone-
receptor pair, pituitary adenylate cyclase-activating peptide (ADCYAP1) and 
pituitary adenylate cyclase-activating peptide receptor (ADCYAP1R), indicated the 
highest significance among these pituitary produced hormone pairs. ADCYAP1 
has been tested as a methylation biomarker for cervical and endometrial cancer 
(Jung et al., 2011; Wentzensen et al., 2014) 
PFS Interaction ER+/PR+         
Gene Symbol β HR 95% CI (HR) adj. p 
ADCYAP1 & ADCYAP1R1 -0.65 0.52 (0.36,0.76) 0.08 
FSHB & FSHR 24.77 5.72E+10 (2153,1.52E+18) 0.23 
LHB & LHCGR 9.58 14473 (15,1.35E+7) 0.23 
     
Table 16. Summary of the Interaction Term for Hormone and Receptor Gene Pairs 
with Expression Levels Associated with PFS for 118 ER+/PR+ Breast Carcinomas. 
As described in Methods and Materials, expression levels of 142 candidate genes 




 When carcinomas expressing ER+/PR- status, six gene pairs were found 
significant with three expressing synergistic and three expressing antagonistic 
effects on the hazard function (Table 17). The effect sizes are large for these six 
pairs but caution should be taken since the sample size is relatively small. 
OS Interaction ER+/PR-         
Gene Symbol β HR 95% CI (HR) adj. p 
SST & SSTR4 8.72 6096.72 (11.48,3237235.64) 0.24 
INHA & ACVR2B -7.11 0 (0,0.13) 0.24 
RLN1 & RXFP1 5.67 289.4 (3.81,22009.88) 0.24 
EPO & EPOR 14.1 1335702.39 (20,8.79E+10) 0.24 
EDN1 & EDNRB -3.83 0.02 (0,0.44) 0.24 
VIP & VIPR1 -3.61 0.03 (0,0.39) 0.24 
     
Table 17. Summary of the Interaction Term for Hormone and Receptor Gene Pairs with 
Expression Levels Associated with OS for 28 ER+/PR- Breast Carcinomas. As described in 
Methods and Materials, expression levels of 142 candidate genes were determined 
using LCM-procured cells from 247 breast cancer biopsies. 
 
For ER-/PR+, two gene pairs were significant for an association with PFS 
and 12 gene pairs were significant for an association with OS (Table 18). There 
should be no surprise to find the pancreatic hormone amylin (IAPP) and its cognate 
pair calcitonin receptor (CALCR) as the most significant pair for assessing the 
relationship with both PFS and OS since its statistical interaction was found to be 
the most significant separately for ER- and PR+ cancers. The heart hormone atrial-
natriuretic peptide (NPPA) and each of its three receptors (NPR1, NPR2 and 
NPR3) had a significant synergistic effect on the hazard for both predicting OS. 




A. PFS Interaction ER-/PR+       
Gene Symbol β HR 95% CI (HR) adj. p 
IAPP & CALCR 7.49 1781.76 (15.68,202470.3) 0.22 
NPPA & NPR3 3.58 35.86 (3.12,411.6) 0.23 
     
B. OS Interaction ER-/PR+        
Gene Symbol β HR 95% CI (HR) adj. p 
IAPP & CALCR 6.71 818.18 (9.23,72540.58) 0.17 
INHBA & ACVR1 0.92 2.52 (1.35,4.7) 0.17 
NPPA & NPR3 3.96 52.38 (3.41,804.52) 0.17 
INHBA & ACVR1B -0.76 0.47 (0.24,0.89) 0.24 
INHBC & ACVR1B 1.09 2.96 (1.27,6.92) 0.24 
INHBC & ACVR2B 0.98 2.66 (1.23,5.74) 0.24 
INHBE & ACVR2A -1.12 0.33 (0.13,0.81) 0.24 
RLN2 & RXFP1 0.85 2.33 (1.14,4.76) 0.24 
CGA & TSHR 0.29 1.34 (1.04,1.72) 0.24 
NPPA & NPR1 11.18 71334.66 (3.98,1.27E+9) 0.24 
NPPA & NPR2 8.94 7617.82 (4.57,1.27E+7) 0.24 
CORT & SSTR5 10.36 31462.61 (3.73,2.65E+8) 0.24 
     
Table 18. Summary of the Interaction Term for Hormone and Receptor Gene Pairs with 
Expression Levels Associated with either PFS (A) or OS (B) for 33 ER-/PR+ Breast 
Carcinomas. As described in Methods and Materials, expression levels of 142 
candidate genes were determined using LCM-procured cells from 247 breast cancer 
biopsies. 
 
 For ER-/PR- cancers, two pairs of hormone-receptor genes showed 
expression levels that exhibited significance for predicting OS (Table 19). HCRT 
and HCRTR2 were found to be significant in both ER- and PR- cancers separately. 
Surprisingly a new gene pair, arginine vasopressin (AVP) and cullin 5 (CUL5) 
appeared with an antagonistic effect on its hazard. CUL5 has been shown to inhibit 




OS Interaction ER-/PR-        
Gene Symbol β HR 95% CI (HR) adj. p 
HCRT & HCRTR2 1.97 7.21 (1.87,27.79) 0.24 
AVP & CUL5 -1.44 0.24 (0.09,0.62) 0.24 
     
Table 19. Summary of the Interaction Term for Hormone and Receptor Gene Pairs with 
Expression Levels Associated with OS for 68 ER-/PR- Breast Carcinomas. As described in 
Methods and Materials, expression levels of 142 candidate genes were determined 
using LCM-procured cells from 247 breast cancer biopsies. 
 
Multivariate Cox Regression for the Hormone of PFS and OS without Regard to 
ER and PR Status of the Cancer Biopsy 
 Two-variable models were employed to evaluate gene expression results 
for the hormones while controlling for all the levels of relative gene expression for 
their cognate receptors. In Table 20, the beta coefficient for the hormone term was 
analyzed for PFS without regard to sex-hormone receptor status. Among the 20 
gene pairs in the Table 20, the hormones with multiple receptors had multiple 
appearances. Each of the hormones were significant for univariate analyses for 
PFS with no significant effect of their betas when accounting for the statistical 
presence of its receptor.  
 In Table 21, the beta coefficient for the hormone term was analyzed for OS 
without regard to sex-hormone receptor status. The strength of the signal from 
POMC regardless its cognate receptor dominated the significance for an 
association for OS. All gene pairs significant for OS were significant for PFS 
including secretin (SCT) with secretion receptor (SCRT) and pancreatic 
polypeptide (PPY) with neuropeptide Y receptor (NPY4R).   
48 
 
PFS Hormone         
Two Gene Model β for Hormone HR 95% CI (HR) adj. p 
POMC + MC1R 0.54 1.71 (1.37,2.15) <0.001 
POMC + MC2R 0.56 1.74 (1.39,2.18) <0.001 
POMC + MC3R 0.54 1.72 (1.37,2.15) <0.001 
POMC + MC4R 0.54 1.72 (1.37,2.15) <0.001 
POMC + MC5R 0.51 1.66 (1.32,2.1) <0.001 
SST + SSTR2 0.56 1.75 (1.29,2.39) 0.007 
SST + SSTR5 0.55 1.74 (1.28,2.36) 0.007 
SST + SSTR3 0.51 1.67 (1.24,2.25) 0.01 
SST + SSTR4 0.54 1.71 (1.25,2.34) 0.01 
PPY + NPY4R 0.96 2.6 (1.35,5.02) 0.05 
CRH + CRHR1 0.54 1.72 (1.17,2.55) 0.07 
REN + ATP6AP2 0.6 1.82 (1.13,2.93) 0.13 
PRL + PRLR 0.32 1.37 (1.06,1.77) 0.15 
SCT + SCTR 0.57 1.78 (1.06,2.97) 0.21 
EDN1 + EDNRA 0.39 1.48 (1.04,2.1) 0.21 
EDN1 + EDNRB 0.4 1.49 (1.05,2.11) 0.21 
RLN1 + RXFP1 -0.21 0.81 (0.67,0.99) 0.28 
RLN1 + RXFP3 -0.2 0.82 (0.67,1) 0.30 
RLN2 + RXFP1 -0.13 0.88 (0.77,1) 0.30 
PTH + PTH2R -1.26 0.28 (0.08,0.99) 0.30 
     
Table 20. Summary of the Hormone Term from Two Variable Cox Models of Hormone 
and Receptor Gene Pairs with Expression Levels Associated with PFS. As described in 
Methods and Materials, expression levels of 142 candidate genes were determined 


















OS Hormone         
Two Gene Model β for Hormone HR 95% CI (HR) adj. p 
POMC + MC1R 0.52 1.68 (1.34,2.1) <0.001 
POMC + MC2R 0.53 1.71 (1.36,2.13) <0.001 
POMC + MC3R 0.52 1.67 (1.34,2.1) <0.001 
POMC + MC4R 0.52 1.68 (1.34,2.1) <0.001 
POMC + MC5R 0.48 1.62 (1.28,2.05) 0.002 
SCT + SCTR 0.77 2.17 (1.24,3.8) 0.13 
PPY + NPY4R 0.88 2.4 (1.16,4.97) 0.30 
     
Table 21. Summary of the Hormone Term from Two Variable Cox Models of Hormone 
and Receptor Gene Pairs with Expression Levels Associated with OS. As described in 
Methods and Materials, expression levels of 142 candidate genes were determined 
using LCM-procured cells from 247 breast cancer biopsies. 
 
Multivariate Cox Regression for the Genes of Hormones of PFS and OS without 
Regard to ER and PR Status of the Cancer Biopsy 
Two-variable models were employed to evaluate gene expression results 
for the receptors while controlling for all the levels of relative gene expression for 
their cognate hormones. In Table 22, the beta coefficient for the receptor term was 
analyzed for PFS without regard to sex-hormone receptor status. Receptors 
appeared in nearly the same order they appeared in univariate analysis for PFS 
with no significant effect on their betas when accounting for the statistical presence 
of its hormone.  
In Table 23, the beta coefficient for the receptor term was analyzed for OS 
without regard to sex-hormone receptor status. Similar to PFS, the receptors 
appeared in the same order as they did for significance in univariate Cox 
regression with no effect seen with the statistical presence of its cognate hormone. 
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This interpretation continues into the subtypes of ER/PR and for the sake of brevity 



















PFS Receptor         
Two Gene Model β for Receptor HR 95% CI (HR) adj. p 
CALCA + CALCR 0.44 1.55 (1.2,2) 0.04 
IAPP + CALCR 0.46 1.58 (1.22,2.03) 0.04 
IGF1 + IGF1R.clone -0.17 0.84 (0.75,0.94) 0.06 
INS + IGF1R.clone -0.17 0.85 (0.76,0.94) 0.07 
CORT + SSTR1 0.62 1.86 (1.24,2.8) 0.07 
SST + SSTR3 0.93 2.53 (1.2,5.35) 0.10 
INHA + ACVR2A 0.31 1.37 (1.08,1.73) 0.10 
INHA + ACVR2B 0.35 1.42 (1.07,1.89) 0.10 
INHBA + ACVR2A 0.29 1.34 (1.06,1.7) 0.10 
INHBA + ACVR2B 0.35 1.42 (1.08,1.87) 0.10 
INHBB + ACVR2A 0.33 1.39 (1.09,1.77) 0.10 
INHBC + ACVR2A 0.32 1.38 (1.08,1.77) 0.10 
INHBC + ACVR2B 0.35 1.42 (1.08,1.87) 0.10 
INHBE + ACVR2A 0.29 1.34 (1.06,1.7) 0.10 
INHBE + ACVR2B 0.35 1.42 (1.08,1.86) 0.10 
AVP + AVPR2 0.91 2.49 (1.19,5.23) 0.10 
CORT + SSTR3 0.96 2.61 (1.25,5.44) 0.10 
VIP + VIPR1 -0.28 0.75 (0.6,0.94) 0.10 
NPY + NPY1R -0.17 0.85 (0.73,0.97) 0.12 
INHBB + ACVR2B 0.32 1.38 (1.04,1.81) 0.13 
ADCYAP1 + VIPR1 -0.25 0.78 (0.62,0.97) 0.13 
GHRL + GHSR -1.14 0.32 (0.12,0.88) 0.14 
NPY + NPY6R -1 0.37 (0.15,0.9) 0.14 
INHBB + ACVR1B 0.27 1.31 (1.02,1.67) 0.15 
GH1 + GHR 0.43 1.54 (1.04,2.28) 0.15 
AGT + RXFP3 1.23 3.42 (1.09,10.76) 0.15 
INS + INSR.AL365454 -0.25 0.78 (0.61,1) 0.17 
INHBA + ACVR1 -0.27 0.76 (0.58,0.99) 0.17 
INHBA + ACVR1B 0.26 1.29 (1.01,1.65) 0.17 
INHBC + ACVR1 -0.28 0.75 (0.57,0.99) 0.17 
INHBC + ACVR1B 0.26 1.29 (1.01,1.65) 0.17 
INHBE + ACVR1B 0.25 1.29 (1.01,1.65) 0.17 
INHA + ACVR1B 0.25 1.28 (1,1.65) 0.17 
INHBE + ACVR1 -0.27 0.76 (0.58,1) 0.17 
     
Table 22. Representative Summary of the Receptor Term from Two Variable Cox Models 
of Hormone and Receptor Gene Pairs with Expression Levels Associated with PFS. As 
described in Methods and Materials, expression levels of 142 candidate genes were 
determined using LCM-procured cells from 247 breast cancer biopsies. 
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OS Receptor         
Two Gene Model β for Receptor HR 95% CI (HR) adj. p 
CALCA + CALCR 0.44 1.55 (1.17,2.06) 0.12 
IAPP + CALCR 0.46 1.58 (1.19,2.1) 0.12 
INS + IGF1R.clone -0.17 0.84 (0.75,0.95) 0.12 
SST + SSTR3 1.11 3.02 (1.34,6.83) 0.12 
IGF1 + IGF1R.clone -0.16 0.85 (0.75,0.96) 0.12 
INHBB + ACVR2A 0.38 1.46 (1.11,1.93) 0.12 
CORT + SSTR3 1.1 3.02 (1.35,6.73) 0.12 
NPY + NPY6R -1.4 0.25 (0.09,0.69) 0.12 
INHA + ACVR2A 0.35 1.42 (1.08,1.87) 0.13 
INHBA + ACVR2A 0.35 1.43 (1.08,1.88) 0.13 
INHBC + ACVR2A 0.36 1.43 (1.08,1.89) 0.13 
INHBE + ACVR2A 0.34 1.41 (1.08,1.85) 0.13 
VIP + VIPR1 -0.31 0.74 (0.57,0.95) 0.17 
NPY + NPY1R -0.2 0.82 (0.69,0.97) 0.17 
INS + IGF1R -0.19 0.83 (0.69,1) 0.18 
IGF1 + IGF1R -0.18 0.83 (0.69,0.99) 0.18 
AGT + RXFP3 1.29 3.65 (1.04,12.78) 0.18 
INHA + ACVR1 -0.35 0.7 (0.51,0.98) 0.18 
INHA + ACVR1B 0.3 1.35 (1.01,1.8) 0.18 
INHA + ACVR2B 0.36 1.44 (1.04,1.99) 0.18 
INHBA + ACVR1B 0.3 1.35 (1.01,1.79) 0.18 
INHBA + ACVR2B 0.35 1.41 (1.03,1.94) 0.18 
INHBB + ACVR1B 0.29 1.34 (1.01,1.77) 0.18 
INHBC + ACVR1B 0.29 1.33 (1,1.77) 0.18 
INHBC + ACVR2B 0.33 1.4 (1.02,1.91) 0.18 
INHBE + ACVR2B 0.32 1.37 (1,1.88) 0.18 
ADCYAP1 + VIPR1 -0.27 0.77 (0.6,0.99) 0.18 
ADCYAP1 + VIPR2 -0.13 0.88 (0.78,0.99) 0.18 
GHRL + GHSR -1.35 0.26 (0.08,0.86) 0.18 
VIP + VIPR2 -0.13 0.87 (0.78,0.99) 0.18 
IAPP + RAMP2 -0.18 0.84 (0.7,1) 0.19 
INHBC + ACVR1 -0.31 0.74 (0.54,1) 0.19 
INHBA + ACVR1 -0.29 0.75 (0.55,1.01) 0.21 
     
Table 23. Representative Summary of the Receptor Term from Two Variable Cox Models 
of Hormone and Receptor Gene Pairs with Expression Levels Associated with OS. As 
described in Methods and Materials, expression levels of 142 candidate genes were 




Kaplan-Meier Plots Discriminating Hormone-Receptor Pairs Whose Expression 
Levels Predict Clinical Outcomes 
 With 115 possible pairs of genes for peptide/protein hormones and their 
cognate receptors, 59 exhibited gene expression levels that were significant for 
the non-parametric log-rank test for PFS and 41 were significant for the non-
parametric log-rank test for OS without regard to receptor status (i.e., ER+, ER-, 
PR+, PR- and ER/PR combinations). Figure 5 has a representative sample of the 
most significant gene pairs from the log-rank test. Three examples are listed for 
cancers with regard to receptor status and one example for ER+/PR+, ER-/PR-, 
ER+, ER-, PR+ and PR-.  There is a complexity to comparing these Kaplan-Meier 
plots to our interaction models. The main effects of the hormone and receptor in 
the interaction models are a stronger driver of the behavior of the four categories: 
above/below the median expression for the hormone and above/below the median 
expression for the receptor. Kaplan-Meier plots are different from our previous 
analyses with univariate and multivariate Cox regression because the magnitude 
of the relative gene expression isn’t considered in the analysis once cancers are 
stratified into their respective groups. One aspect to consider when evaluating 
these plots is the behavior of cancers that exhibit both elevated hormone and 
receptor gene expression levels. 
Without regard to ER/PR status, the PFS expressed in Kaplan-Meier plots 
for SST & SSTR1 and SST & SSTR3 show a contrasting difference between 
cancers exhibiting the worst prognosis that express mRNA levels of the hormone 
and receptor above the median and cancers with the best prognosis that express 
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the mRNA levels of hormone and receptor below the median (Figure 4). Three 
plots discriminated cancers expressing mRNA above the median for the hormone 
and receptor as the worst prognostic group, which included the OS without regard 
to ER/PR status for POMC and MC5R, the OS for patients with ER+ cancers for 
SST and SSTR2 and the PFS for patients with ER-/PR- cancers for ADCYAP1 and 
VIPR2. For ER+/PR+ cancers, EDN1 & EDNRA was significant for OS for the 
interaction term from multivariate Cox regression. EDN1 & EDNRA was also 
significant for OS for KM plots with cancers expressing both the hormone and 
receptor below the median resulting in the best prognosis. Gene expression results 
shown in the Kaplan-Meier plots for  AVP & AVPR2 (ER-, OS), MLN & MLNR (PR+, 
PFS) and PTH & PTH2R (PR-, PFS), are representative of discordant pairs (i.e., 
above the median expression of the hormone gene and below the median 
expression of the receptor gene) as the group of patients with the poorest 
prognosis.  Although the molecular basis for this predicted clinical behavior is 
unknown currently, the gene expression patterns warrant further research to 
determine if they may be useful in predicting clinical outcomes. 
Multivariable Gene Expression Model fitted using the LASSO  
 The use of regularization techniques such as LASSO allowed us to evaluate 
gene expression levels of all 142 gene candidates to a model by penalizing the 
number of parameters in the model. The analyses were performed for predicting 
either PFS or OS without regard to either ER or PR receptor status, as well as in 
relationship to the four different combinations of ER/PR. Using the loss function to 
decide which model is the best, only three groups showed the minimal loss function 
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not equal to all zeroes for beta coefficients. In other words, all but three models 
exhibited their best fitted models having coefficients with all zeroes, which 
translates to having no significant variables associated with PFS and OS when a 
penalty is put on the size of the beta coefficients. 
 The LASSO fitted and cross-validated model for predicting breast cancer 
outcome expressing ER+/PR+ status for predicting OS was composed of 
expression levels of seven hormone genes (IGF1, INHBB, GNRH2, PENK, 
CALCA, GAL and PTMS) and those for nine receptor genes (SSTR2, SSTR3, 
SSTR4, PRLHR, EPOR, PRLR, CUL5, NPY2R and NPY5R) (Table 24). Strikingly, 
expression results of each of the eight genes showing statistical significance in 
univariate Cox regression analyses for predicting OS of ER+/PR+ cancers 
reappeared in the model derived from LASSO. The LASSO derived model of gene 
expression results for predicting PFS of ER-/PR- cancers was composed of  five 
hormone genes (AGT, POMC, GH1, PRL and PTH) and five receptor genes 
(CALR, SSTR1, AGTRAP, AVPR1A and AVPR2). Expression levels of these ten 
genes were all significant for predicting PFS of ER-/PR- cancers from univariate 
analyses. The LASSO derived model for prediction of PFS of ER- breast cancers 
was composed of four hormone genes (POMC, GH1, LHB and SCT) and two 
receptor genes (CALCR and AVPR1A). Expression levels of these six genes were 
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Figure 5. Representative Kaplan-Meier Plots Comparing Above and Below the Median 
Relative Gene Expression for Peptide/Protein Hormones and Their Cognate Receptors. 
Cancers with above the median expression for the hormone and the receptor have the 
worst prognosis (A (n=247), B (n=247), C (n=247), E (n=68), F (n=146)). ER+/PR+ cancers 
with below the median expression for both the hormone and receptor have the best 
prognosis. (D (n=118)) Cancers with below the median expression for the hormone and 
above the median expression for the receptor have the worst prognosis (G (n=101), I 
(n=96)). Cancers with above the median expression for the hormone and below the 





A. OS ER+/PR+   B. PFS ER-/PR-   C. PFS ER- 
Gene Symbol β   Gene Symbol β   Gene Symbol β 
SSTR2 2.01  CALCR 0.17  CALCR 0.35 
SSTR3 1.04  SSTR1 0.03  POMC 0.31 
SSTR4 0.17  AGT 0.14  GH1 -0.40 
IGF1 -0.31  AGTRAP -0.09  LHB 0.05 
INHBB -0.59  POMC 0.31  SCT 0.13 
GNRH2 0.39  GH1 -0.38  AVPR1A 0.23 
PRLHR -0.78  PRL 0.10    
PENK -0.06  AVPR1A 0.12    
EPOR 0.12  AVPR2 0.21    
PRLR 0.42  PTH -0.07    
CUL5 -0.41       
CALCA 1.27        
GAL 0.08       
NPY2R 0.34       
NPY5R -0.03       
PTMS 0.19       
        
Table 24. Significant Genes and Corresponding Beta Coefficients for LASSO Performed 
on 142 Peptide/Protein Hormones and Their Cognate Receptors With and Without 
Receptor Status of Breast Carcinomas. ER+/PR+ cancers for OS (A), ER-/PR- cancers for 
PFS (B) and ER- cancers for PFS (C) were significant models from LASSO with a 
maximized likelihood from an L1 penalty and cross-validation.      
 
Discussion 
 The expansion of our analysis with multivariate techniques intended to 
exhaust all the relationships hormones and receptors may have on each other. 
Two variable models proved to be no better at predicting PFS and OS than their 
respective univariate models. However, the interaction models gave us a myriad 
of questions to be answered, which is exactly what an exploratory based study 
should do.  
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 Interaction models allowed us to explore the idea of endocrine autonomy 
where a cancer cell produces hormone proteins that bind to its own receptor 
proteins. This self-promoting loop could be associated with signaling pathways for 
proliferation. The idea that cancer cells have autonomous mechanisms to promote 
proliferation is not new (Hanahan & Weinberg, 2000). In addition, we know of a 
few peptide proteins which have been researched as biomarkers for early cancer 
detection (Assiri, Kamel, & Hassanien, 2015; Bae, Schaab, & Kratzsch, 2015). Yet 
to the best of our knowledge no one as looked at these peptide/protein hormones 
and their cognate receptors collectively.  
What we have revealed with the novel findings from significant gene pairs 
for interaction are potential gene pairs to be used in a molecular model to predict 
cancer prognosis or potential targets for therapy. Throughout our exhaustive 
search through related literature, we found no studies that employed the use of 
statistical interaction to develop their molecular signatures to predict cancer 
behavior. For future studies we would like to investigate combinations of these 
significant genes for interaction to develop a unique molecular signature. Hormone 
therapy treatment with tamoxifen blocks the estrogen receptor site, thus disrupting 
the function of the receptor signaling inside the cell. If further investigation reveals 
a pathway for proliferation through one of our many hormone-receptor pairs, then 
specific targets could be developed to block those receptor sites. 
The Kaplan-Meier plots offered us the best visual understanding of the 
relationship between hormones and their cognate receptors. The distinction drawn 
from cancers expressing high levels of hormones and receptor genes and those 
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expressing low levels of hormone and receptor genes suggests a strong dose-
response for predicting PFS and OS (i.e., (A) SST and SSTR3 and (B) SST and 
SSTR1 in Figure 5). Significant Kaplan-Meier plots with a single group exhibiting 
a worse prognosis spawn exploratory ideas such as why do patients with cancers 
expressing high levels of the hormone motilin (MLN) and low levels of its cognate 
receptor MLNR have a significantly worse prognosis compared to the other three 
groups (Figure 5 (H)). The best way to embark on an investigation of one of these 
anomalies is to culminate univariate and multivariate Cox regressions, ER/PR 
boxplots and Kaplan-Meier plots for the hormone and receptor. Thus, these results 
serve as a platform for further investigation. 
LASSO was performed on all 142 peptide/protein hormones and their 
cognate receptors to evaluate which genes were being expressed with the 
strongest signals for predict PFS and OS. The only non-zero models materialized 
from ER/PR subtypes. This suggests that the role of the sex hormones play a 
larger role in the behavior of peptide/protein hormones and receptors in predicting 
PFS and OS than trying to predict PFS and OS without considering the ER/PR 
receptor status. Receptor status is essential to determining the type of treatment 
a patient receives. Further examination of our findings may provide better 
prognosis for breast cancer patients across multiple biomarkers especially with the 
molecular signatures developed in Chapter IV. 
 




META-ANALYSIS AND MOLECULAR SIGNATURES 
 To strengthen our findings of specific genes whose expression predicts 
clinical behavior of breast cancer, we extended our analyses by examining our 
results with those reported in several public databases. The unique nature of the 
HRL dataset, having been developed using RNA extracted from Laser Capture 
Micro-dissected breast carcinoma cells, made direct comparisons to results of 
each of the four public databases examined difficult since none of them used LCM 
techniques in their studies.  Therefore, it was reasoned that the meta-analysis 
would be conducted using various approaches of combining the HRL dataset with 
the public databases to determine the relationships of expression of genes for the 
142 peptide/protein hormone and their cognate receptors related to clinical 
outcomes of  breast carcinoma patients (Figure 1 Flow Diagram).  
Methods and Material 
Public Databases 
One of the widely accepted practices is to externally validate the significant 
findings of our study using public datasets. Four public databases, TRANSBIG, 
VDX, MAINZ and UNT, were chosen based on the strength of their studies and 
their accessibility through Gene Omnibus Expression (GEO).  Gene 
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expression values and clinical measurements were downloaded using the 
Bioconductor (version 3.2) packages ‘breastCancerTRANSBIG’, 
‘breastCancerVDX’, ‘breastCancerMAINZ’ and ‘breastCancerUNT’. Microarray 
data of relative gene expression levels determined with the AffymetrixU133a 
GeneChip were reported by TRANSBIG, VDX, MAINZ and UNT. TRANSBIG 
contained results from 198 lymph-node negative patients treated at five different 
centers. (Buyse et al., 2006) (Desmedt et al., 2007) VDX reported the relative gene 
expression results from 286 lymph-node negative patients with primary breast 
cancer. (Wang et al., 2005) The MAINZ database contained results from 200-node 
negative patients. (Schmidt et al., 2008) while UNT reported gene expression 
levels of 189 lymph-node negative patients. (Sotiriou et al., 2006) Each of the four 
public databases employed in these investigations contained the levels of estrogen 
receptor expressed in each cancer biopsy. 
 Prior to performing meta-analysis, the relative expression levels of each of 
the 142 candidate genes were normalized to a mean of zero and standard 
deviation of one within each of the five datasets. The relative gene expression 
results of the HRL database and those of the four public databases, in various 
combinations, were concatenated into individual datasets. No weight was given to 
any dataset nor to any subset of patients based on their characteristics (e.g., ER 
status of the cancer). Using each of the combined datasets, univariate Cox 
regression and multivariate Cox regression analyses were performed with gene 
expression results of each of the 142 candidate genes using only the clinical 
outcome PFS/RFS and the status of the biomarker, ER. 
62 
 
Molecular Signatures and Multivariable Cox Model 
The field of 142 candidate genes was constricted to a smaller specialized 
group by a predefined criterion. In order for a gene to meet the criterion it must be 
significant (p < 0.05) for univariate Cox regression in the HRL data analysis and at 
least one other public database. This technique gives a higher preference for the 
HRL dataset, which is the only database to use LCM on its tissue biopsies.      
These genes were selected as the special candidates for a molecular 
signature to be modeled with training and test sets using the meta-analyses 
dataset. Initially, the patients were placed into subsets based on their ER status 
since ER status is a strong predictor of clinical outcome. Patients were randomly 
selected into a 70% training set and the other 30% of patients were placed in a 
test set. Equal proportions of ER+ and ER- patients were selected to reflect the 
same proportion in the entire population. This randomization was independently 
repeated 1000 times.  
Each training set was evaluated using Least Absolute Shrinkage and 
Selection Operator (LASSO) with an L1 penalty determined by the optL1 command 
in the penalized package. An L1 penalty shrinks the beta coefficients of non-
significant genes to zero. The genes in each model were tallied after 1000 
iterations. The number of gene occurrences in the training models was then 
compared to the maximum gene occurrence in permuted data sets. The permuted 
sets were constructed by randomly reordering the patient’s clinical outcomes 
against their gene expression values. This approach established a baseline for the 
noise in the data as well as identified the genes with the strongest signals. Any of 
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the genes within the training set that contain a higher frequency than the maximum 
frequency in the permuted set were considered to be significant. (S. A. Andres et 
al., 2015) 
Linear predictors were determined with the training set models and applied 
to the remaining 30% (test sets). A linear predictor is constructed for each patient 
by the summation of the relative gene expressions for each gene in the model 
multiplied by each gene’s beta coefficient. The linear predictors were segregated 
into above/below the median subsets. Kaplan-Meier plots were constructed for the 
median splits using all models that had predictors in them. In order to visually 
compare these plots an alternative Kaplan-Meier plot was constructed which 
permuted the clinical outcomes (progression free survival, recurrence) against 
their corresponding linear predictors. These alternative plots should have no 
recognizable pattern between the median and tertiary split subsets. The 
distributions of the p-values from the non-zero Cox models, median splits, and 
tertiary subsets are shown in boxplots.   
In order to externally validate the genes in our molecular signatures (MS), 
the four public databases were divided into 1000 training (70%) and test (30%) 
sets. The beta coefficients determined by Cox regression with the genes in each 
of the molecular signatures were applied to their corresponding test set. These 
linear predictors were evaluated against the clinical outcomes of the test set using 
the concordance index (C-index). Boxplots were employed on the 1000 C-indices 
to illustrate their distributions. The R command rcorrcens in R package Hmisc 
64 
 
calculated the C-index for each linear predictor and set of clinical outcomes (RFS 
for TRANSBIG and UNT and DMFS for VDX and MAINZ). 
Results 
Meta-analysis of HRL and Four Public Databases  
 Univariate Cox regression performed on 1126 breast cancer biopsies (HRL 
and four public databases combined) for each of the 142 candidate genes resulted 
in 12 genes exhibiting unadjusted p-values < 0.07. After p-values were adjusted 
for multiple comparisons using the Benjamin-Hochberg method, no genes met the 
0.3 discovery threshold. Two limitations of this analysis are the clinical outcome 
being measured by MAINZ and VDX ignore local metastasis as an event and none 
of the public databases utilized LCM to avoid the convolution of surrounding non-
cancerous tissues in their analyses. Despite limitations and loss of significance 
after controlling for the false discovery rate, RLN2, RLN1, VIPR1 and ACVR1B 
appear later in our 14-gene molecular signature for cancers without regard to 
receptor status.  
 Univariate Cox regression performed on 737 ER+ breast cancer biopsies 
for each of the 142 candidate genes resulted in eight genes exhibiting an 
association with PFS/DMFS and unadjusted p-values less than 0.04. Univariate 
Cox regression performed on 378 ER- breast cancer biopsies for each of the 142 
candidate genes resulted in 13 genes exhibiting an association with PFS/DMFS 
and unadjusted p-values less than 0.07. After adjusting p-values for multiple 
comparisons, the expression of genes in neither ER+ nor ER- cancers exhibited  
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Gene Symbol β HR 95% CI (HR) p adj. p 
RLN2 -0.14 0.87 (0.78,0.96) 0.01 0.69 
GHR 0.12 1.13 (1.03,1.25) 0.01 0.69 
FSHB -0.12 0.89 (0.81,0.98) 0.02 0.69 
VIPR2 -0.11 0.89 (0.81,0.99) 0.02 0.69 
ADCYAP1 0.1 1.11 (1,1.23) 0.04 0.69 
VIPR1 -0.1 0.91 (0.83,1) 0.05 0.69 
TRH -0.1 0.9 (0.81,1) 0.06 0.69 
RLN1 -0.09 0.91 (0.83,1) 0.06 0.69 
SSTR3 0.09 1.1 (1,1.21) 0.06 0.69 
ACVR1B 0.1 1.1 (1,1.22) 0.06 0.69 
TMSB10 0.09 1.1 (1,1.21) 0.06 0.69 
THPO 0.09 1.1 (1,1.21) 0.06 0.69 
      
Table 25. Summary of the Genes from Meta-analysis without Regard to Receptor Status 
(n=1126) with Expression Levels Associated with PFS/DMFS. As described in Methods 
and Materials, expression levels of 142 candidate genes were determined using LCM-
procured cells from 247 breast cancer biopsies. 
 
adjusted p-values less than the 0.3 threshold. The unadjusted univariate 
associated gene, GRP, for ER+ cancers appears in the 3-gene molecular 
signature for ER+ breast cancers while the unadjusted univariate associated 
genes, IGF1 and POMC, for ER- cancers appear in the 9-gene molecular signature 








A. PFS/DMFS ER+        
Gene Symbol β HR 95% CI (HR) p adj. p 
RLN2 -0.19 0.82 (0.72,0.94) 0.01 0.45 
THPO 0.15 1.16 (1.03,1.31) 0.01 0.45 
PRLR 0.15 1.17 (1.02,1.33) 0.02 0.45 
SST 0.15 1.16 (1.02,1.32) 0.02 0.45 
C19orf80 -0.15 0.86 (0.76,0.98) 0.02 0.45 
ACVR1B 0.14 1.15 (1.02,1.31) 0.03 0.45 
GRP -0.14 0.87 (0.77,0.98) 0.03 0.45 
ATP6AP2 0.15 1.16 (1.02,1.33) 0.03 0.45 
      
B. PFS/DMFS ER-        
Gene Symbol β HR 95% CI (HR) p adj. p 
IGF1 0.22 1.25 (1.06,1.46) 0.01 0.63 
PTMS 0.22 1.25 (1.05,1.49) 0.01 0.63 
AVPR2 0.18 1.2 (1.02,1.4) 0.02 0.63 
GHR 0.16 1.18 (1.02,1.37) 0.03 0.63 
POMC 0.15 1.16 (1.01,1.33) 0.03 0.63 
TSHB -0.19 0.83 (0.7,0.99) 0.04 0.63 
VIPR2 -0.17 0.84 (0.71,0.99) 0.04 0.63 
GALR3 -0.17 0.84 (0.71,0.99) 0.04 0.63 
LEPR 0.16 1.17 (1,1.37) 0.05 0.63 
RAMP2 0.15 1.16 (1,1.36) 0.05 0.63 
C19orf80 0.15 1.16 (0.99,1.36) 0.06 0.63 
INSR 0.14 1.14 (0.99,1.32) 0.06 0.63 
CAP2 -0.15 0.86 (0.74,1.01) 0.06 0.63 
      
Table 26. Summary of the Meta-analysis for (A) ER+ (n=737) and (B) ER- (n=378) Breast 
Cancers with Expression Levels Associated with PFS/DMFS. As described in Methods 
and Materials, expression levels of 142 candidate genes were determined using LCM-








Kaplan-Meier Plots Demonstrating Results from Meta-Analysis 
 The Kaplan-Meier plots in Figure 6 compare the difference between breast 
cancers reported in the public databases and in the HRL database expressing a 
gene above and below the median. The three most significant genes are shown 
for the 1126 cancers without regard to receptor status, 737 ER+ cancers and 378 
ER- cancers (11 cancers had missing data on ER status). For breast cancers 
without regard to receptor status, patients with cancers that expressed ADCYAP1 
and SST above the median and VIPR2 below the median had the worst prognosis. 
Noteworthy, SST and VIPR2 appear in the 14-gene molecular signature (Figure 
7). Patients with ER+ breast cancers expressing SST and SSTR2 above the 
median and RAMP2 below the median tend to have a shorter time for a recurrence 
of cancer. Interestingly, SSTR2 also appears in the 3 –gene molecular signature. 
Patients with ER- breast cancers expressing C19orf80 above the median and TRH 
and FSHB below the median exhibited the worst prognosis.   
 Gene Signatures Predicting Clinical Behavior of Breast Carcinomas 
Significant genes from univariate Cox regression, either PFS or OS, were 
analyzed for their ability to predict risk of breast cancer recurrence as a set with 
1000 LASSO training/test sets. The genes that occurred in more models than in 
the permuted set, which serves as the null distribution, are considered gene 
signature candidates until externally compared with results in public databases, as 
described in Methods and Materials. A 14-gene subset was identified as a 
candidate molecular signature for predicting clinical outcome without regard to the 
sex hormone receptor status of the breast cancer biopsies (Figure 7). When sex-
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hormone receptor status was considered, a three-gene signature composed of 
NPY1R, SSTR2 and GRP was deciphered for ER+ breast cancer biopsies and a 
candidate 9-gene signature was identified for ER- breast cancer biopsies.  
The 14-gene signature was composed of expression patterns for eight 
receptor genes and six hormone ligand genes. Of these 14 genes, only NPY1R 
was also identified in the 3-gene signature in ER+ breast cancers (Figure 7). 
Interestingly, three of the genes, POMC, CALCR and PRL, of the signature 
deciphered without regard for ER status were also found in the 9-gene signature 
identified in ER- breast cancers. Surprisingly, in contrast to the composition of the 
14-gene signature, only two of the 9 genes of the molecular signature associated 
with ER- breast cancer direct the synthesis of hormone receptors. No genes 
reflecting peptide/protein hormone-receptor pairs were detected in the 14-gene 
signature nor in the 3-gene signature. It is noteworthy, that the gene for the 
hormone prolactin (PRL), which plays a central role in breast physiology, and 
prolactin’s cognate receptor PRLR appeared in the 9-gene signature for ER- 
biopsies.  
 Concordance indices evaluated the predictive ability of the genes in each 
of the three molecular signatures on each of the four public databases. Figure 8 
summarizes the distribution of the C-indices determined by 1000 training and test 
sets. The 9-gene MS performed better than the 14-gene and 3-gene MS in VDX, 
UNT and MAINZ and as well as the 3-gene model in TRANSBIG. The median C-
index for the 9-gene model was greater than 0.6 for two public databases, MAINZ 
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and UNT. Excitingly, the best predictive MS is in the 9-gene model for ER- cancers, 
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Figure 6. Representative Kaplan-Meier Plots Comparing Above and Below the Median Relative 
Gene Expression of 142 Peptide/Protein Hormones or Their Cognate Receptors with and without 
Regard to ER Status for PFS from the Meta-analysis. Without regard to ER status, 1126 breast 
carcinomas expressing ADCYAP1 (A) and SST (C) above the median and VIPR2 (B) below the 
median had the worst prognosis. 737 ER+ breast carcinomas expressing RAMP2 (D) below the 
median and SST (E) and SSTR2 (F) above the median had the worst prognosis. 378 ER- breast 
carcinomas expressing TRH (G) and FSHB (H) below the median and C19orf80 (I) above the 
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Figure 8. Summary of 1000 C-indices of Each of the Three Molecular Signatures on Each 
of the Four Public Databases, (A) VDX, (B) TRANSBIG, (C) UNT and (D) MAINZ. The 14-
Gene MS was applied to cancers without regard to receptor status. The 3-Gene MS and 
9-Gene MS was applied to ER+ and ER- cancers, respectively. Validation of the genes in 
the three MS was performed by dividing public databases into 70% training and 30% 






 As expressed earlier, our overarching goal is to determine the relationships 
of the expression of the genes for each of the peptide/protein hormones and that 
of their cognate receptors with clinical outcomes of breast cancer patients. Our 
hypothesis is that expression profiles of subsets of these genes for regulatory 
molecules may be used to predict risk of breast carcinoma recurrence in patients 
with primary disease. It appears that our approach described in Figure 1 is original 
considering the following resources: 1) only de-identified breast cancer tissues 
were processed by LCM for microarray, 2) gene expression levels reflected only 
mRNA of specific cell types, 3) 22,000 genes were determined in 247 primary 
breast carcinomas in a standardized fashion and 4) data were complemented by 
quantitative results of protein biomarker levels (ER, PR and HER-2). These 
unparalleled properties of each specimen were accompanied by clinical follow-up 
and patient outcome. A multitude of statistical analyses such as univariate and 
multivariate Cox regressions, Kaplan-Meier plots, boxplots and LASSO were 
utilized to predict a patient’s clinical outcome. 
 Recall from Chapter II the importance POMC, GH1 and CALCR contributed 
to predicting PFS and OS for univariate Cox regression and Kaplan-Meier plots for 
ER- subtypes of breast carcinomas. SST and its cognate receptors diverge 
expression towards cancers exuding estrogen receptor proteins (ER+). POMC is 
the standout gene from univariate Cox regression with and without regard to 
receptor status while GH1 in ER- cancers displayed an exceptional differentiation 
between cancers expressing the gene at high and low levels. POMC has appeared 
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in many studies showing an association with a variety of diseases such as obesity 
and cancer (Clark, 2015; Mountjoy, 2015). Other studies have shown 
polymorphisms of GH1 to have a protective influence on breast cancer risk 
(Wagner et al., 2006). Although we did not examine polymorphism, we did 
independently show that elevated levels GH1 in breast carcinomas have a 
protective effect. These findings warrant further the investigation of these two 
genes with the HRL’s Next Generation Sequencing (NGS) database. 
 Chapter III explored a myriad of multivariate predictors for progression of 
disease and survivorship of patients with primary breast cancers. A number of 
hormone-receptors exhibited a significant statistical interaction such as the pairs 
HCRT-HCRTR2 in ER- and PR- cancers, IAPP-CALCR in ER- cancers and FSHB-
FSHR in ER+/PR+ cancers. Two variable models did not distinguish any better 
predictors for PFS and OS than univariate Cox regression results contributed. 
LASSO revealed the prominence of the role that sex hormone status performs in 
predicting PFS and OS for peptide/protein hormones and their receptors.  The 
significant LASSO results of 16 genes for ER+/PR+ cancers, 10 genes for ER-/PR- 
cancers and 6 genes for ER- will be externally validated with the public databases 
as alternative molecular signatures in future studies. 
 We learned from Chapter IV that the significance of many genes in the 
meta-analysis evaporated when adjusted for multiple comparison were calculated. 
This loss in the number of significant genes happened throughout the study. The 
challenge of exploring the relative expression levels of 142 genes is not just the 
volume of work to be organized but discretizing statistical significance from the 
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inherent noise of highly correlated data found in microarray. Our original answer 
to the question of how to validate our discoveries since most of them could not 
overcome the loss of significance from adjusting for a false discovery rate was the 
use of public databases. The challenge was the lack of public databases that used 
LCM to ensure only cancer cells were being evaluated and the uncertainty of their 
consistency used in specimen collection and lab techniques.  
Despite these challenges, our 9-gene molecular signature for ER- cancers 
performed better than the 14 gene and 3-gene MS in predicting the PFS/DMFS in 
all four public databases. The median concordance index of two public databases 
was over 60%. In summary, the resources and approach clearly support the 
integrity of the molecular signatures primary breast carcinoma to predict risk of 
recurrence. Additional steps in the clinical validation of these signatures may 
include the implementation of a clinical trial whereby the molecular signatures are 
used as biomarkers with and without regard to sex hormone receptor status of the 














Alldinger, I., Dittert, D., Peiper, M., Fusco, A., Chiappetta, G., Staub, E., . . . Ockert, D. (2005). 
Gene expression analysis of pancreatic cell lines reveals genes overexpressed in 
pancreatic cancer. Pancreatology, 5(4-5), 370-379.  
Andres, S. A., Bickett, K. E., Alatoum, M. A., Kalbfleisch, T. S., Brock, G. N., & Wittliff, J. L. (2015). 
Interaction between smoking history and gene expression levels impacts survival of 
breast cancer patients. Breast cancer research and treatment, 152(3), 545-556.  
Andres, S. A., Bickett, K. E., Alatoum, M. A., Kalbfleisch, T. S., Brock, G. N., & Wittliff, J. L. (2015). 
Interaction between smoking history and gene expression levels impacts survival of 
breast cancer patients. Breast Cancer Res Treat, 152(3), 545-556. doi:10.1007/s10549-
015-3507-z 
Andres, S. A., Brock, G. N., & Wittliff, J. L. (2013). Interrogating differences in expression of 
targeted gene sets to predict breast cancer outcome. BMC Cancer, 13(1), 1.  
Andres, S. A., Edwards, A. B., & Wittliff, J. L. (2012). Expression of Urokinase‐Type Plasminogen 
Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI‐1) in Human Breast Carcinomas 
and Their Clinical Relevance. Journal of clinical laboratory analysis, 26(2), 93-103.  
Andres, S. A., & Wittliff, J. L. (2011). Relationships of ESR1 and XBP1 expression in human breast 
carcinoma and stromal cells isolated by laser capture microdissection compared to 
intact breast cancer tissue. Endocrine, 40(2), 212-221.  
Andres, S. A., & Wittliff, J. L. (2012). Co-expression of genes with estrogen receptor-α and 
progesterone receptor in human breast carcinoma tissue. Hormone molecular biology 
and clinical investigation, 12(1), 377-390.  
Assiri, A., Kamel, H. F., & Hassanien, M. F. (2015). Resistin, visfatin, adiponectin, and leptin: risk 
of breast cancer in pre-and postmenopausal saudi females and their possible diagnostic 
and predictive implications as novel biomarkers. Disease markers, 2015.  
Austin, P. C., & Tu, J. V. (2004). Automated variable selection methods for logistic regression 
produced unstable models for predicting acute myocardial infarction mortality. Journal 
of clinical epidemiology, 57(11), 1138-1146.  
Bae, Y. J., Schaab, M., & Kratzsch, J. (2015). Calcitonin as Biomarker for the Medullary Thyroid 
Carcinoma Medullary Thyroid Carcinoma (pp. 117-137): Springer. 
Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: a practical and 
powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B 
(Methodological), 289-300.  
Bradburn, M. J., Clark, T. G., Love, S. B., & Altman, D. G. (2003). Survival Analysis Part II: 
Multivariate data analysis – an introduction to concepts and methods. British Journal of 
Cancer, 89(3), 431-436. doi:10.1038/sj.bjc.6601119 
Burnatowska-Hledin, M. A., Kossoris, J. B., Van Dort, C. J., Shearer, R. L., Zhao, P., Murrey, D. A., . 
. . Barney, C. C. (2004). T47D breast cancer cell growth is inhibited by expression of 




Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., . . . Consortium, T. (2006). 
Validation and clinical utility of a 70-gene prognostic signature for women with node-
negative breast cancer. J Natl Cancer Inst, 98(17), 1183-1192. doi:10.1093/jnci/djj329 
Chen, A., Kaganovsky, E., Rahimipour, S., Ben-Aroya, N., Okon, E., & Koch, Y. (2002). Two Forms 
of Gonadotropin-releasing Hormone (GnRH) Are Expressed in Human Breast Tissue and 
Overexpressed in Breast Cancer A Putative Mechanism for the Antiproliferative Effect of 
GnRH by Down-Regulation of Acidic Ribosomal Phosphoproteins P1 and P2. Cancer 
Research, 62(4), 1036-1044.  
Clark, A. J. (2015). 60 YEARS OF POMC: The proopiomelanocortin gene: discovery, deletion and 
disease. Journal of molecular endocrinology, JME-15-0268.  
Córdoba-Chacón, J., Gahete, M. D., Pozo-Salas, A. I., Martínez-Fuentes, A. J., de Lecea, L., Gracia-
Navarro, F., . . . Luque, R. M. (2011). Cortistatin is not a somatostatin analogue but 
stimulates prolactin release and inhibits GH and ACTH in a gender-dependent fashion: 
potential role of ghrelin. Endocrinology, 152(12), 4800-4812.  
Cormier, E. M., Wolf, M. F., & Jordan, V. C. (1989). Decrease in estradiol-stimulated 
progesterone receptor production in MCF-7 cells by epidermal growth factor and 
possible clinical implication for paracrine-regulated breast cancer growth. Cancer Res, 
49(3), 576-580.  
Desmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., . . . Consortium, T. 
(2007). Strong time dependence of the 76-gene prognostic signature for node-negative 
breast cancer patients in the TRANSBIG multicenter independent validation series. Clin 
Cancer Res, 13(11), 3207-3214. doi:10.1158/1078-0432.CCR-06-2765 
Falzon, M., & Du, P. (2000). Enhanced Growth of MCF-7 Breast Cancer Cells Overexpressing 
Parathyroid Hormone-Related Peptide 1. Endocrinology, 141(5), 1882-1892.  
Fisher, B., Brown, A., Wolmark, N., REDMOND, C., Wickerham, D. L., Wittliff, J., . . . PRAGER, D. 
(1987). Prolonging tamoxifen therapy for primary breast cancer: Findings from the 
National Surgical Adjuvant Breast and Bowel Project clinical trial. Annals of internal 
medicine, 106(5), 649-654.  
Fisher, B., Dignam, J., Tan-Chiu, E., Anderson, S., Fisher, E. R., Wittliff, J. L., & Wolmark, N. 
(2001). Prognosis and treatment of patients with breast tumors of one centimeter or 
less and negative axillary lymph nodes. Journal of the National Cancer Institute, 93(2), 
112-120.  
Fisher, B., Redmond, C., Brown, A., Wickerham, D., Wolmark, N., Allegra, J., . . . Wittliff, J. (1983). 
Influence of tumor estrogen and progesterone receptor levels on the response to 
tamoxifen and chemotherapy in primary breast cancer. Journal of Clinical Oncology, 
1(4), 227-241.  
Fisher, B., Redmond, C., Brown, A., Wolmark, N., Wittliff, J., Fisher, E. R., . . . Wolter, J. (1981). 
Treatment of primary breast cancer with chemotherapy and tamoxifen. New England 
Journal of Medicine, 305(1), 1-6.  
Fleisher, M., Dnistrian, A. M., Sturgeon, C. M., Lamerz, R., & Wittliff, J. L. (2002). Practice 
guidelines and recommendations for use of tumor markers in the clinic. Tumor markers: 
physiology, pathobiology, technology and clinical applications, 33-63.  
Gingras, I., Desmedt, C., Ignatiadis, M., & Sotiriou, C. (2015). CCR 20th Anniversary Commentary: 
Gene-Expression Signature in Breast Cancer—Where Did It Start and Where Are We 
Now? Clinical Cancer Research, 21(21), 4743-4746.  
Ginsburg, E., & Vonderhaar, B. K. (1995). Prolactin synthesis and secretion by human breast 
cancer cells. Cancer Research, 55(12), 2591-2595.  
Goeman, J., Meijer, R., & Chaturvedi, N. (2014). L1 and L2 penalized regression models: R. 
78 
 
Goeman, J. J. (2010). L1 penalized estimation in the Cox proportional hazards model. Biometrical 
journal, 52(1), 70-84.  
Greenspan, F. S., Gardner, D. G., & Shoback, D. (1997). Basic & clinical endocrinology: Appleton 
& Lange Stamford, CT. 
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., . . . Hayes, 
M. (2010). American Society of Clinical Oncology/College of American Pathologists 
guideline recommendations for immunohistochemical testing of estrogen and 
progesterone receptors in breast cancer (unabridged version). Archives of pathology & 
laboratory medicine, 134(7), e48-e72.  
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. cell, 100(1), 57-70.  
Hanukoglu, I. (1992). Steroidogenic enzymes: structure, function, and role in regulation of 
steroid hormone biosynthesis. J Steroid Biochem Mol Biol, 43(8), 779-804. 
doi:10.1016/0960-0760(92)90307-5 
Hong, Y., & Chen, S. (2011). Aromatase, estrone sulfatase, and 17β-hydroxysteroid 
dehydrogenase: Structure–function studies and inhibitor development. Molecular and 
cellular endocrinology, 340(2), 120-126.  
Hoyer, D., Bell, G. I., Berelowitz, M., Epelbaum, J., Feniuk, W., Humphrey, P. P., . . . et al. (1995). 
Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci, 16(3), 
86-88.  
James, L. W. (1984). Steroid hormone receptors in breast cancer. Cancer, 532(2), 630.  











Jung, S., Yi, L., Jeong, D., Kim, J., An, S., Oh, T.-J., . . . Kim, K. I. (2011). The role of ADCYAP1, 
adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early 
detection of cervical cancer. Oncology reports, 25(1), 245-252.  
Kaushal, S., & Sinha, M. (2015). WORLD JOURNAL OF PHARMACEUTICAL RESEARCH.  
Kerr II, D. A., & Wittliff, J. L. (2011). A five-gene model predicts clinical outcome in ER+/PR+, 
early-stage breast cancers treated with adjuvant tamoxifen. Hormones and Cancer, 2(5), 
261-271.  
Kidd, L. R., Brock, G. N., VanCleave, T. T., Benford, M. L., Lavender, N. A., Kruer, T. L., & Wittliff, J. 
L. (2010). Angiogenesis-associated sequence variants relative to breast cancer 
recurrence and survival. Cancer Causes & Control, 21(10), 1545-1557.  
Klein, J. P., & Moeschberger, M. L. (1997). Survival analysis techniques for censored and 
truncated data.  Retrieved from http://site.ebrary.com/id/10005871 
79 
 
Klein, J. P., & Moeschberger, M. L. (2003). Survival analysis : techniques for censored and 
truncated data (2nd ed.). New York: Springer. 
Kruer, T. L., Cummins, T. D., Powell, D. W., & Wittliff, J. L. (2013). Characterization of estrogen 
response element binding proteins as biomarkers of breast cancer behavior. Clinical 
biochemistry, 46(16), 1739-1746.  
Langevin, S. M., Kratzke, R. A., & Kelsey, K. T. (2015). Epigenetics of lung cancer. Translational 
Research, 165(1), 74-90.  
Lee, Y. S., Challis, B. G., Thompson, D. A., Yeo, G. S., Keogh, J. M., Madonna, M. E., . . . Farooqi, I. 
S. (2006). A POMC variant implicates beta-melanocyte-stimulating hormone in the 
control of human energy balance. Cell Metab, 3(2), 135-140. 
doi:10.1016/j.cmet.2006.01.006 
Ma, X., Wang, W., Salunga, R., Tuggle, T., Stecker, K., Baer, T., . . . Wittliff, J. (2003). Gene 
expression signatures associated with clinical outcome in breast cancer via laser capture 
microdissection. Paper presented at the Breast cancer research and treatment. 
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., Clark, G. M., & Statistics 
Subcommittee of, N. C. I. E. W. G. o. C. D. (2006). REporting recommendations for tumor 
MARKer prognostic studies (REMARK). Breast Cancer Res Treat, 100(2), 229-235. 
doi:10.1007/s10549-006-9242-8 
Metzler, M. A., Venkatesh, S. G., Lakshmanan, J., Carenbauer, A. L., Perez, S. M., Andres, S. A., . . 
. Darling, D. S. (2015). A systems biology approach identifies a regulatory network in 
parotid acinar cell terminal differentiation. PLoS One, 10(4), e0125153.  
Mountjoy, K. (2015). Pro‐Opiomelanocortin (POMC) Neurones, POMC‐Derived Peptides, 
Melanocortin Receptors and Obesity: How Understanding of this System has Changed 
Over the Last Decade. Journal of neuroendocrinology, 27(6), 406-418.  
Norman, A. W., & Litwack, G. (1997). Hormones: Academic Press. 
Pierce, J. G. (1982). Protein and peptide hormones. Stroudsburg, Pa. :: Hutchinson Ross Pub. Co. 
Raloxifene Hydrochloride.   Retrieved from http://www.cancer.gov/about-
cancer/treatment/drugs/raloxifenehydrochloride 
Rich, J. T., Neely, J. G., Paniello, R. C., Voelker, C. C., Nussenbaum, B., & Wang, E. W. (2010). A 
practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg, 
143(3), 331-336. doi:10.1016/j.otohns.2010.05.007 
Rodrigues-Ferreira, S., & Nahmias, C. (2015). G-protein coupled receptors of the renin-
angiotensin system: new targets against breast cancer? Frontiers in pharmacology, 6.  
Sachdev, D. (2008). Regulation of breast cancer metastasis by IGF signaling. Journal of mammary 
gland biology and neoplasia, 13(4), 431-441.  
Schmidt, M., Bohm, D., von Torne, C., Steiner, E., Puhl, A., Pilch, H., . . . Gehrmann, M. (2008). 
The humoral immune system has a key prognostic impact in node-negative breast 
cancer. Cancer Res, 68(13), 5405-5413. doi:10.1158/0008-5472.CAN-07-5206 
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., . . . Delorenzi, M. (2006). Gene 
expression profiling in breast cancer: understanding the molecular basis of histologic 
grade to improve prognosis. J Natl Cancer Inst, 98(4), 262-272. doi:10.1093/jnci/djj052 
Surveilance, Epidemiology, and End Results Program.   Retrieved from 
http://seer.cancer.gov/statfacts/html/breast.html 
Tamoxifen Citrate.   Retrieved from http://www.cancer.gov/about-
cancer/treatment/drugs/tamoxifencitrate 
Tecimer, C., Doering, D., Goldsmith, L., Meyer, J., Abdulhay, G., & Wittliff, J. (2000). Clinical 
relevance of urokinase‐type plasminogen activator, its receptor and inhibitor type 1 in 
ovarian cancer. International Journal of Gynecological Cancer, 10(5), 372-381.  
80 
 
Therneau, T. (2013). A package for survival analysis in S. R package version 2.37-4. URL 
http://CRAN. R-project. org/package= survival. Box, 980032, 23298-20032.  
Tikk, K., Sookthai, D., Fortner, R. T., Johnson, T., Rinaldi, S., Romieu, I., . . . Clavel-Chapelon, F. 
(2015). Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a 
case-control study. Breast Cancer Res, 17, 49.  
Toremifene.   Retrieved from http://www.cancer.gov/about-
cancer/treatment/drugs/toremifene 
Van Dort, C., Zhao, P., Parmelee, K., Capps, B., Poel, A., Listenberger, L., . . . Clare, P. (2003). 
VACM-1, a cul-5 gene, inhibits cellular growth by a mechanism that involves MAPK and 
p53 signaling pathways. American Journal of Physiology-Cell Physiology, 285(6), C1386-
C1396.  
Wagner, K., Hemminki, K., Grzybowska, E., Klaes, R., Burwinkel, B., Bugert, P., . . . Pamula, J. 
(2006). Polymorphisms in genes involved in GH1 release and their association with 
breast cancer risk. Carcinogenesis, 27(9), 1867-1875.  
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., . . . Foekens, J. A. (2005). 
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary 
breast cancer. Lancet, 365(9460), 671-679. doi:10.1016/S0140-6736(05)17947-1 
Wentzensen, N., Bakkum‐Gamez, J. N., Killian, J. K., Sampson, J., Guido, R., Glass, A., . . . Rush, B. 
(2014). Discovery and validation of methylation markers for endometrial cancer. 
International Journal of Cancer, 135(8), 1860-1868.  
Wittliff, J., Ma, X., Stecker, K., Salunga, R., Tuggle, J., Tran, Y., . . . Pistone, M. (2002). Gene 
expression profiles and tumor marker signatures of human breast carcinoma cells 
procured by laser capture microdissection. Endocrine Soc Abs, 3, 538.  
Wittliff, J., Pasic, R., & Bland, K. (1998). Steroid and peptide hormone receptors: methods, 
quality control and clinical use. The Breast: Comprehensive Management of Benign and 
Malignant Diseases. Philadelphia, PA, WB Saunders Co, 458-498.  
Wittliff, J. L. (2010). Laser Capture Microdissection and Its Use in Genomics & Proteomics, in 
Reliable Lab Solutions. In P. M. Conn (Ed.), Techniques in Confocal Microscopy (pp. 463-
477): Elsevier Press. 
Wu, M., & Singh, A. K. (2012). Single-cell protein analysis. Current opinion in biotechnology, 
23(1), 83-88.  
Yang, Y., & Yee, D. (2012). Targeting insulin and insulin-like growth factor signaling in breast 















Michael W. Daniels 
 
911 Mallard Creek Road 
Louisville, KY 40207 
(502) 693-4229 (cell) 





Graduate Program, University of Louisville 
 Master of Science Biostatistics 
 Department of Public Health and Information Sciences 
 
Graduate Research Assistant, University of Louisville 
 Department of Biochemistry & Molecular Genetics 
      Hormone Receptor Laboratory  
- Commonwealth of Kentucky (State License #200078  
Endocrinology & Chemistry) 
82 
 
- Health Care Financing Administration (Federal License –  
CLIA #18D0648476, Endocrinology) 
 
Student Member, Institute for Molecular Diversity &  
 Drug Design (IMD3), University of Louisville 
 




Master of Science Biostatistics 
Aug. 2014 – Current (expected May 2016) 




Bachelor of Science Mathematics 
Concentration: Pure Mathematics 
January 2012 - May 2014 






Honors and Awards 
 
Travel Award, IMD3 – Partial funding to attend the San Antonio Breast Cancer 
Symposium and co-present two posters.  
 
Travel Award, School of Public Health – Partial funding to attend the San Antonio 




Feb. 2015 - Current 
Graduate Research Assistant, Hormone Receptor Laboratory 
 Use of various statistical software packages including R to analyze 
complex genomics and proteomics results in a comprehensive database 
of biochemical and clinical studies of human cancer.  
 Development of presentation formats for meetings, grant applications and 
reports 
 Supervise statistical studies of two undergraduate research fellows. 
 
2011 - Current 
Donor Center Coordinator, Kentucky Organ Donor Affiliates 
 Accurately screen potential donors for medical suitability. 
 Counsel potential donor families regarding their donation options. 
84 
 
 Obtain consent for appropriate organs and/or tissues and conduct 
medical/social history interviews with families. 
 
National & International Research Meeting - Abstracts 
 
Wittliff JL, Daniels MW, Brock GN. Expression of Genes for Peptide/Protein 
Hormones and Their Receptors in Breast Carcinomas as Biomarkers Predicting 
Risk of Recurrence, 2015 San Antonio Breast Cancer Symposium (SABCS), in 
press. 
 
Sanders MA, Daniels MW, Wittliff JL. Expression of genes for aromatase 
inhibitor targets to discriminate invasive lobular from invasive ductal carcinomas 
of the breast using LCM-procured cells to complement endocrine biomarkers, 
2015 San Antonio Breast Cancer Symposium (SABCS), in press. 
 
Mentored Abstracts  
 
Hameed ZR, Sereff SB, Wittliff JL, Daniels MW. Deciphering the Molecular Basis 
of Breast Cancer Behavior using Proteomics and Genomics, Posters-at-the-








American Statistical Association, member. 
American Association for Cancer Research, member. 




Served nine years in Virginia National Guard and US Army Reserves as an 
enlisted infantryman. 
 
Competed at a national M60 competition for all branches of US military service. 
(1st place in 2-mile run with 800 meter shot) 
 
Mobilized for Operation Noble Eagle in 2002. 
 
 
